Tissue-resident immune cells reside in distinct niches across organs, where they contribute to tissue homeostasis and rapidly respond to perturbations in the local microenvironment. Innate lymphoid cells (ILCs) are a family of innate immune cells that regulate immune and tissue homeostasis. Across anatomical locations throughout the body, ILCs adopt tissue-specific fates, differing from circulating ILC populations. Adaptations of ILCs to microenvironmental changes have been documented in several inflammatory contexts, including obesity, asthma, and inflammatory bowel disease. While our understanding of ILC functions within tissues have predominantly been based on mouse studies, development of advanced single cell platforms to study tissue-resident ILCs in humans and emerging patient-based data is providing new insights into this lymphocyte family. Within this review, we discuss current concepts of ILC fate and function, exploring tissue-specific functions of ILCs and their contribution to health and disease across organ systems.

Keywords: innate lymphoid cell (ILC), NK cell, tissue-resident immune cells, tissue homeostasis, autoimmunity, inflammation, immune tolerance

INTRODUCTION

Innate lymphoid cells (ILCs) orchestrate immune responses to signals such as cytokines, alarmins, neuropeptides and hormones, interacting with hematopoietic and non-hematopoietic cells alike. ILCs lack rearranged antigen receptors and while predominantly tissue-resident, are also observed in circulation and secondary lymphoid tissues where they exhibit distinct spatial and temporal functions (1). Outside of roles in immunity, ILCs have key roles in maintaining tissue homeostasis, promoting tissue repair, and regulating inflammation. Via crosstalk with parenchymal cells, ILCs are also involved in processes previously thought to lack immune system influence, such as thermal regulation, neuronal signal transduction, circadian rhythms, and tissue remodeling (2–6). The regulation of both immune functions and tissue-specific processes by ILCs highlights the importance of understanding how they respond and function within tissue niches, and conversely how ILC biology is controlled by the microenvironment in which they reside.

Development of ILCs in non-lymphoid tissues occurs when circulating ILC progenitors seed tissue niches, and requires the expression of local survival factors including IL-7 and thymic stromal lymphopoietin (TSLP) (7, 8). Differentiated ILCs express signature cytokines and transcription factors that parallel CD4+ and CD8+ T cells in both humans and mice (Figure 1) (6, 8), and can be
broadly categorized as cytotoxic (NK cells) or non-cytotoxic ‘helper’ ILCs. Human NK cells express TBET and Eomesodermin (EOMES), release IFN-γ and TNF-α and are grouped into CD56^{dim}CD16^{+} or CD56^{bright}CD16^{−} NK cells. CD56^{dim}CD16^{+} NK cells express killer cell immunoglobulin-like receptors (KIRs) and exhibit profound cytotoxic potential (6, 8). CD56^{bright}CD16^{−} NK cells lack KIR expression but are superior producers of IFN-γ and TNF-α (9, 10). NK cells discriminate between self and non-self or altered-self and function in anti-viral and anti-tumor immunity similarly to CD8^{+} cytotoxic T cells (6, 8). ‘Helper’ ILCs (hILCs) are non-cytotoxic and are classified based on function and development into Group 1 (ILC1s), Group 2 (ILC2s), Group 3 (ILC3s) as well as Lymphoid Tissue inducer LTi cells (6). ILC1s produce IFN-γ in a TBET-dependent but EOMES-independent manner (6). ILC2s express GATA-3 and RORγt and secrete interleukin (IL)-4, IL-5, IL-9, IL-13 and Amphiregulin (AREG), aiding in anti-parasite immunity or the promotion of allergic responses (6). ILC3s rely on the transcription factor RORC and produce IL-22, IL-17, and GM-CSF (6). ILC3s include subsets which express natural cytotoxicity receptors (NCRs) NKP44 (human) and NKP46 (mouse and human). LTi cells express ILC3-associated transcription factors and cytokines but also express surface Lymphotoxin (sLT) (11). Further, ILCs with ILC3-associated transcription factors and cytokines but also express surface Lymphotoxin (sLT) (11). These include both NK-like ILCs, IL-10 producing ILC2s (ILC210) and ID3^{+} regulatory ILCs [reviewed in Jegatheeswaran et al. (19)]. Despite growing appreciation of ILCs with regulatory functions, their development and function are poorly characterized, particularly in humans.

Mouse studies identified central roles for ILCs in regulating tissue homeostasis, repair and remodeling, transforming our understanding of cellular interactions between immune cells and the tissues in which they reside. Across tissue microenvironments, ILCs adapt and acquire distinct phenotypes and functional properties (Figure 2). While ILC subsets have important functions within these tissues, dysregulation of ILC numbers and functions is associated with diverse human pathologies including arthritis, diabetes, psoriasis, asthma, and inflammatory bowel disease [reviewed in (20)], highlighting the need to identify how local tissue factors promote or inhibit inflammatory ILC responses. Within this review, we explore NK cell and hILC biology across different tissues in health and disease, highlighting evidence of similarities between human and mouse ILC function where data is available. We summarize current understanding of organ-specific functions of ILCs, focusing on their contributions to tissue homeostasis, host-defense, and inflammatory disease progression across the body.

**ILCs in the Nervous System**

While the central nervous system (CNS) is considered an immune-privileged site with minimal immune infiltrate, ILCs have been identified in the CNS of healthy humans and mice, accounting for ~2.5% of leukocytes by sequencing (21–25). CNS-resident NK cells are present in low proportions in the naïve mouse brain and enriched in a IL-2Rα^{+} CD27^{+} CD62L^{high} subset, suggesting a more mature phenotype compared to infiltrating NK cells (22). CNS ILC2s accumulate with age and reside in the healthy murine meninges, localizing within dural sinuses and surrounding blood vessels (23–25). Interestingly, the transcriptional profile of meningeal ILC2s showed downregulation of genes related to metabolism, signal transduction, and inflammation compared to lung-derived ILC2s, suggesting a tissue-specific quiescent adaptation to the CNS environment (23). Upon spinal cord injury in mice, ILC2s migrate to the injured site independently of IL-33 and upregulate Calca (CGRP) and its receptor Ramp3, associated with nerve regeneration (23), yet the regenerative activity of ILC2s in the spinal cord remains to be demonstrated experimentally.

**ILCs in Multiple Sclerosis**

Multiple sclerosis (MS) is a demyelinating and neurodegenerative autoimmune disease that is one of the most common neurological disabilities in young adults (26). NK cells mediate several treatment-related effects in MS patients (Figure 3A). For example, Daclizumab targets the high affinity IL-2 receptor (CD25), inhibiting activated T cells and resulting in greater availability of IL-2, which expands CD56^{bright} NK cells expressing high levels of the medium-affinity IL-2 receptor chain (CD122) (18, 27). This expansion of CD56^{bright} NK cells or elevated baseline expression of CD122 in patients correlated with lower inflammation and fewer inflammatory lesions (18, 28). While T cells are only modestly depleted by Daclizumab directly, induction of T cell apoptosis by CD56^{bright} NK cells is supported by findings of Granzyme K^{+} NK cell co-localization with T cells in active MS lesions (18, 29, 30). Takahashi et al. further found that during the remission phase of MS, CD95 expression increased on NK cells alongside decreased response of memory T cells, suggesting that CD95^{+} NK cells regulate autoimmunity memory T cell responses during remission (31). In autologous hematopoietic stem cell transplantation, another MS treatment modality, NK cells reconstitute faster than CD4^{+} T cells with controversial effects on the abundance of NK cells in the cerebrospinal fluid of patients with MS compared to those with other inflammatory and non-inflammatory neurological diseases, suggesting an MS-specific alteration in resident NK cells with controversial effects on the abundance of NK cells in circulation (30, 33, 34). Despite conflicting findings regarding abundance, circulating CD56^{bright} NK cells from MS patients have reduced IFN-γ production in response to IL-12 and an impaired ability to regulate autologous CD4^{+} T cells compared to healthy controls (33, 35). This impaired regulatory capacity was due to HLA-E upregulation on autologous T cells engaging the inhibitory receptor NKG2A on NK cells (35). Further, DNAM-1 and 2B4 were reduced on NK cells alongside reduced expression of the DNAM-1 ligand CD155 on CD4^{+} T cells, while Daclizumab treatment induced CD155 upregulation on T cells to partially rescue the impaired ability of NK cells to regulate autologous T cells (30). A genome-wide association study of MS patients demonstrated lower expression of TBX21 and EOMES in...
NK cells, supporting that impairment of NK cells may be a driver of MS (36).

Using the experimental autoimmune encephalomyelitis (EAE) model of MS, Hao et al. demonstrated the importance of CX3CR1-mediated recruitment in generating disease-ameliorating CNS-resident mouse NK cells (37). Transmigration of NK cells into the CNS partially depends on VLA-4 binding to endothelial VCAM-1, as antibody blockade of VLA-4 reduces NK cell recruitment by 40-70% (30, 38). Absence from or blocked transmigration results in excessive proliferation of myelin-reactive CD4+ T helper 17 (Th17) cells, indicating that NK cells must be within the CNS to limit myelin-specific T cell activity and disease progression (37).

Mouse NK cell-mediated disease amelioration required an NCR- and perforin-dependent lysis of microglia to abrogate Th17 expansion (37). The tight proximity of microglia and NK cells requires reciprocal chemoattraction through secretion of MIP-1α and MCP-1 by NK cells and microglia, respectively (37, 39). Additionally, NK cells dampen EAE pathogenesis by directly modulating infiltrating CCR2°Ly6Chigh monocytes in an acetylcholine-dependent fashion. Adoptive-transfer of choline acetyltransferase (ChAT)-expressing NK cells into the CNS of Cx3cr1−/− mice reduced the abundance of infiltrating monocytes (40). ChAT+ NK cells dampened TNF-α, IL-1β, IL-12 and Qa-1 expression by monocytes through engaging the α7-nicotinic acetylcholine receptor, rendering myeloid cells more susceptible to lysis (40). ChAT+ NK cells preferentially localize to active demyelinated lesions in the human brain, suggesting this mechanism of microglial regulation may translate to human MS as well (40). While dampening myeloid and T cell activity reduces disease severity, murine NK cells negatively impact regeneration through lysis of Qa-1low neuronal stem cells in the sub-ventricular zone, altering neuronal repair and impairing recovery in later disease (41). Of note, NK cell activation via NKG2D triggered motor neuron destruction in models of amyotrophic lateral sclerosis (42).

**FIGURE 1** | Common phenotypic markers of mice (top) and human (bottom) ILCs and their common cytokine expression profiles. Cytotoxic: Natural Killer cells can be subdivided into two major subsets based on surface marker expression in both mice and humans. In mice, NK cells are subdivided into two subsets based on CD27 and CD11b expression: CD27highCD11b− immature NK cells and mature CD27lowCD11b+ NK cells. In humans, CD56brightCD16- and CD56dimCD16+ are generally used to identify immature and mature NK cells in blood. However, tissue NK cells often display a CD56brightCD16− phenotype. ILC1s, ILC2s, and ILC3s are classified based on surface marker and transcription factor expression profiles that parallel CD4+ T helper subsets. ILC3s are further subdivided into natural cytotoxicity receptor (NCR)+ and NCR− subsets. Created with Biorender.org.
sclerosis, suggesting pathological NK cell-mediated lysis of neurons is not specific to MS/EAE (42).

Other ILCs have been identified in MS too, although inconsistent phenotyping has hindered identification of these ILCs. A sizable fraction of CD3⁻ IL-17⁺ RORγt⁺ cells associate with newly formed meningeal lymphoid follicles of MS patients, suggestive of ILC3 involvement (43). In mice, CD3⁻ RORγt⁺ populations in the cerebellum after EAE induction were predominantly CD4⁻, consistent with ILC3 identity (44). Hatfield et al. reported both NCR⁺ and NCR⁻ ILC3s and CD4⁺ CD3⁻ LTi-like ILC3s within the meninges of healthy mice which proliferated and accumulated downstream of c-kit signaling during EAE induction (45). Meningeal ILC3s produce IL-17 and GM-CSF, and express co-stimulatory molecules OX40L.
and CD30L. They accumulated near Th17 cells and antigen presenting cells (APCs) and facilitated T cell activation and entry into the brain parenchyma in a T-bet-dependent fashion, highlighting a role for ILC3s in establishing a microenvironment that sustains Th17 responses in EAE (45, 46).

Helper ILCs (hILCs) are also affected by Daclizumab treatment and appear to play a sex-biased role in MS/EAE. Untreated MS patients presenting with elevated white blood cell counts displayed higher levels of RORC2+ ILCs and dampened Th17-associated inflammation by lowering IL-17 and GM-CSF. ChAT+ NK cells preferentially localize to demyelinated lesions in the human brain to dampen monocyte-driven inflammation via the α7-nicotinic acetylcholine receptor (α7nAChR), rendering myeloid cells more susceptible to lysis at early stages of MS. Conversely, NK cell-mediated lysis negatively impacts regeneration during later stages of MS by targeting, Qa-1low neuronal stem cells. NK cell activation may be impaired by NKG2A/HLA-E interactions with autologous CD4+ T cells. (B) After a stroke, CX3CL1 from hypoxic neurons recruits NK cells, while local IL-15 levels facilitate NK cell enrichment and promote high NKG2D expression and neuronal lysis. (C) ILC2s impact neurological functions in murine brain and are supported by exogenous IL-33 to suppress T cell inflammation and enhance neurogenesis. Created with Biorender.org.

FIGURE 3 | ILCs in the nervous system. Limited information exists on human ILCs in the nervous system at steady state due to challenges in obtaining samples, however, several studies focus on ILC activity in multiple sclerosis or stroke. (A) Daclizumab-driven inhibition of T cells resulted in the expansion of NK cells and the elevated lysis of T cells. Daclizumab treatment lowers the abundance of Lin− c-kit+RORC2+ ILCs and dampens Th17-associated inflammation by lowering IL-17 and GM-CSF. ChAT+ NK cells preferentially localize to demyelinated lesions in the human brain to dampen monocyte-driven inflammation via the α7-nicotinic acetylcholine receptor (α7nAChR), rendering myeloid cells more susceptible to lysis at early stages of MS. Conversely, NK cell-mediated lysis negatively impacts regeneration during later stages of MS by targeting, Qa-1low neuronal stem cells. NK cell activation may be impaired by NKG2A/HLA-E interactions with autologous CD4+ T cells. (B) After a stroke, CX3CL1 from hypoxic neurons recruits NK cells, while local IL-15 levels facilitate NK cell enrichment and promote high NKG2D expression and neuronal lysis. (C) ILC2s impact neurological functions in murine brain and are supported by exogenous IL-33 to suppress T cell inflammation and enhance neurogenesis. Created with Biorender.org.

Murphy et al. Tissue-Adapted Functions of ILCs
Frontiers in Immunology | www.frontiersin.org March 2022 | Volume 13 | Article 8369995
ILCs in Cerebral Ischemia (Stroke)

After a stroke, human peripheral blood NK cells are reduced early (<72h) and the degree of reduction as well as expression of activation markers positively correlates with infarct volume (51, 52). Within 12 hours of intracerebral hemorrhage, CD69“Perforin” NK cells become the dominant immune cell type in perihematatorial regions (21). 24h following a stroke, CD69“Nkp46” cell numbers peaked in the brain and remained elevated (52). In mice, the accumulation of NK cells during the acute phase of stroke is mediated by the release of CX3CL1 by hypoxic neurons (53). Recruited NK cells accumulate in an IL-15-rich environment, adopt an activated phenotype, and mediate neuronal lysis through missing-self activation (Figure 3B) (53). Ischemia-reperfusion injury (IRI) induces IL-15 production by neurons, astrocytes and microglia, blockade of which reduced IFN-γ NK cells in the murine brain (54). Liu et al. reported that cholinergic signaling in the brain and catecholaminergic signaling in the periphery suppressed NK cell function after cerebral ischemia, contributing to post-stroke susceptibility to infection (52). While adrenergic activation suppressed NK cell abundance and function in the periphery, cholinergic signaling reduces Runx3 expression in CNS NK cells, leading to a decline in NK cell responsiveness and demonstrating the involvement of distinct neural pathways in regulating the spatial activation of NK cells in mice and humans (52). In humans, the microRNA (miRNA) profile of peripheral NK cells is altered after stroke and inhibition of miRNA-451a and miRNA-122-5p partially restored CD69 and NKG2D expression, suggesting that targeting miRNAs may alleviate immunosuppression observed after a stroke (51). Although data supporting a role for helper ILCs in response to stroke is scarce, early after an acute cerebral infarction circulating ILC1s increased and ILC2s decreased, correlating to serum ox-LDL levels, suggesting lipid-mediated regulation of ILC1 and ILC2 abundance (55).

ILCs in Neurological Function

Murine studies support a role for ILCs in regulating neurological function. Depletion of NK cells using anti-NK1.1 improved cognitive function, enhanced neurogenesis, and reduced microglial inflammation but did not affect β-amyloid concentration in a mouse model of Alzheimer’s disease (56). NK cells exhibited altered expression profiles in the disease model, with higher expression of Icam1, Ctsb, Ctsc, Ccl3 and Ccl4 (56). Following NK cell depletion, microglia exhibited a return to homeostatic morphology, reduced proliferation, and reduced expression of pro-inflammatory mediators including Il18, Il1a, Il1b and Tnf, suggesting that NK cells and type I immunity contribute to cognitive decline by promoting microglial inflammation (56). In line with these findings, choroid plexus ILC2s accumulated and displayed a quiescent state in the aged brain, which was reversed with IL-33 stimulation (57). In comparison to meningeal ILC2s, choroid plexus ILC2s were resistant to senescence and exhibited higher expression of Arg1 and genes associated with glycolysis that may underlie their enhanced proliferative and cytokine-producing capacity, and suggest niche-specific functionality (57).

Intriguingly, activation of ILC2s in aged mice or transfer of activated ILC2s to the aged brain increased cognitive function, potentially through IL-5-mediated suppression of T cell inflammation leading to enhanced neurogenesis (Figure 3C) (57). After traumatic brain injury, ILCs are increased in frequency in human meninges and cerebrospinal fluid, and treatment with AMPK-activating metformin in a murine model specifically enhanced IL-10-producing ILC2s and improved neurological outcomes (58). Together, this suggests that ILC2s support neurological function and resolution of inflammation while NK cells exacerbate cognitive decline.

ILCs in Peripheral Nervous System

Nervous system signaling in the periphery is also impacted by ILC activity. Specialized pro-resolving mediators (SPMs) such as PCTR1 are important for resolving inflammation and promoting tissue repair (59). Acetylcholine promotes the enzymatic activity of ILC3-derived 15-LOX-1, the initiating enzyme in PCTR1 biosynthesis (60). Production of SPMs is regulated by the vagus nerve, and loss of vagus nerve signaling reduced peritoneal ILC3s in mice resulting in poor resolution of Escherichia coli infection (60). The circuit between ILC3s, SPMs, and macrophages is key for resolving infection and inflammation in the peritoneum (60).

ILCs in the Lung

NK cells account for 10-20% of all lymphocytes in human and murine lungs (61–63). Lung NK cells are marked by higher CD57 and KIR expression, and lower CD27, indicative of a mature phenotype (64). Despite their high KIR expression, human lung CD56dimCD16+ NK cells are hypofunctional and some CD56bright subsets are characterized by the expression of markers associated with tissue-residency (e.g., CD69, ITGA1 (CD49a), ITGAE (CD103), and CXCR6) (61, 64). A review by Hervier et al. nicely summarizes the development and function of NK cell subsets in the human lung (65). In addition to NK cells, all other helper ILC subsets have been observed in human lung, albeit with conflicting reports on the relative abundance of ILC1s, ILC2s and ILC3s that may reflect small sample sizes, sampling location, or inter-donor heterogeneity (66, 67).

Recruitment as well as local proliferation of ILC precursors in the lung during development shape the pool of tissue-resident ILC subsets (Figure 4A). Oherle et al. identified that murine pulmonary ILC3s develop from a local precursor pool sustained by insulin-like growth factor 1 provided by alveolar fibroblasts (68). Early-life seeding of ILC3s was protective against pneumonia in a CCR4-dependent fashion, driven by a gut commensal microbiota – dendritic cell (DC) axis (69). Similar interactions between adventitial stromal cells and mouse ILC2s were reported to sustain and regulate ILC2s homeostasis and function (24, 70). Adventitial stromal cells release TSLP, promoting basal IL-13 release by ILC2s, which in turn activates adventitial stromal cells to produce IL-33 in a homeostatic circuit (24). Interestingly, ILC2s localize around...
**FIGURE 4** | ILCs in the lung. At homeostasis (A), IL-22 producing ILC3s are required for protection against pneumonia and require commensal gut bacteria for their recruitment to the lungs. Once in the lung, ILC3s are sustained locally through insulin-like growth factor 1 (IGF1) from alveolar fibroblasts. In the steady state, Adventitial stromal cell-derived TSLP promotes IL-13 production by ILC2s that drives stromal cells to produce IL-33. During pulmonary tuberculosis (PTB), ILC3 accumulation in the lung is regulated by pathogen-derived AhR-ligands that in turn promote phagocyte function, formation of tertiary lymphoid structures and enhanced protection. Similarly, infection by influenza virus triggers Nkp46-dependent activation of NK cells resulting in IL-12 and type 1 interferon secretion by DCs that promote NK cell activation. The release of CCL8 and IL-33 during respiratory viral infection facilitated ILC2 activation and AREG-dependent epithelial repair. In allergic lung inflammation, IL-13 from ILC2s induced Th2 cell differentiation by promoting migration of activated DCs to the draining lymph nodes. In mice, administration of the CRTH2 ligand, prostaglandin D2, promotes ILC2 accumulation. Nociceptor Nav1.8+ sensory neurons activated lung ILC2s through vasoactive intestinal peptide (VIP), while pulmonary neuroendocrine cells produced calcitonin gene related-peptide (CGRP) collectively promoting allergic inflammation in the murine lung. Nasal polyps accumulate ILC2s in chronic rhinosinusitis, which supports eosinophils and promotes chronic airway inflammation. IL-17A+IL-22+ ILCs and NCR- ILC3s are increased in COPD. The lungs of COPD patients and smokers contain Neuruplin 1 (NRP1)-expressing ILC2s surrounding high endothelial venules. NK cells may contribute to COPD, with higher CD67 expression, IL-15-dependent activation, and greater cytotoxicity against lung epithelial cells.

*Created with Biorender.org.*
the peribronchial and perivascular adventitial cuff regions independent of microbial signals, IL-25, IL-33 or TSLP, indicating that additional unknown signals regulate pulmonary ILC2 development and recruitment (24, 70, 71). Whether pulmonary ILC2s in mice and humans originate from other tissues at steady state remains unclear, however mouse intestinal ILC2s were demonstrated to traffic to the lungs in an S1P-dependent manner after intraperitoneal IL-25 administration or helminth infection, demonstrating coordination between tissue sites to resolve multi-organ infections (72). Additional niche-sIGNALS may be delivered through the ICOS: ICOSL axis that has been demonstrated to sustain the pool of pulmonary ILC2s by elevating anti-apoptotic genes and IL-2 responsiveness (73). Intriguingly, ILC2s express both ICOS and ICOS-L, suggesting that both self-sustaining and helper cell-dependent interactions promote ILC2 homeostasis (73).

ILCs in Airway Infections

Airborne pathogens are a constant challenge within the lung, and ILCs have a key role in anti-bacterial and anti-viral host defense (Figure 4B). Helper ILCs accumulate in the lungs of patients with pulmonary tuberculosis (PTB), while circulating ILCs are reduced (74), suggesting trafficking of ILCs to the lung. ILC3s are critical for host defense in PTB, as specific deletion of ILC3s (Ahr
ddRor	c cre) increased mycobacterial burden, and impaired the accumulation of alveolar macrophages and formation of protective lymphoid follicles in granulomas (74). Mycobacterial pigments serve as ligands for Aryl hydrocarbon receptor (AHR), a key transcription factor for ILC3 development and function, suggesting an alternative mechanism of ILC3 activation in tuberculosis infection (75). In addition, ILC3s recruited to murine lungs produced IL-17A and IL-22 to enhance protection and support phagocytic functions of inflammatory monocytes to mediate clearance of bacterial infections (76, 77).

NK cells are critical in controlling viral infections in the lung. Indeed, influenza infection is lethal in Ncr1-/- mice (78). However, adoptive transfer and antibody-depletion experiments showed that NK cells exacerbated influenza morbidity and mortality in a manner dependent on virus titer (79). Differences in mouse genetic backgrounds, influenza strains, and infectious dosage complicate the interpretation and translation of these findings. In humans, viral hemagglutinin on infected cells triggered NKp46-dependent activation of NK cells, and upregulation of the NKG2D ligand ULBP on infected DCs and elevated secretion of IL-12 and type 1 interferon facilitated NK cell activation and cytolyis in response to influenza (80, 81). In a human lung tissue explant model, CD56brdCD49ay NK cells robustly responded to influenza A infection, hinting at an NK cell subset-specific memory response (82). Dou et al. found that seasonal influenza vaccination induced a short-term (6 month) memory response in NK cells, correlating with downregulation of surface NKp46 and a concomitant increase in intracellular NKp46 expression (83). This memory response to re-challenge was not strain-specific, suggesting broader protection to influenza after seasonal strain-specific vaccination (83). While the role of ILC1s separate from NK cells is less clear, murine ILC1s promote antiviral defense and DC maturation, potentially through the glucocorticoid-induced TNFR-related protein (GITR):GITR-L axis (84). GITR upregulation on ILC1s resulted in stronger IFN-γ and TNF-α responses to influenza A, supporting host defense against alveolar viral infections (84).

ILCs have conflicting roles in influenza infection response, promoting airway hyperreactivity in an IL-13-dependent manner while supporting epithelial cell integrity and tissue repair via the secretion of AREG following viral infections (85, 86). In response to CCL8, IL-33-activated ILC2s produce more IL-5 and IL-13, and exhibit ameboid-like movements to traffic to peribronchial and perivascular sites in mice, particularly at locations of increased collagen-I deposition (71). Human ILC2s also exhibited a chemotactic response to CCL8, suggesting shared lung recruitment responses across species (71). Infections with respiratory syncytial virus (RSV) leads to a viral titer-independent increase in respiratory disease severity in young infants driven by elevated ILC2 cytokine release (87, 88). Interestingly, patients older than 3 months had fewer ILC2s in their lungs, greater IFN-γ levels and experienced less severe disease, suggesting that the immunological changes occurring with age and development confer protection to RSV infections by balancing type 1 and type 2 immunity (88). The plasticity of ILC2s may also play a role in promoting type 1 immunity to viral infections. Silver et al. found that adoptively transferred murine ILC2s trans-differentiate into ILC1s near IL-12- and IL-18-expressing myeloid cells during influenza A infection (89). Overall, this suggests that age and plasticity shape ILC2 responses to viral infections.

ILCs in Asthma and Allergic Airway Inflammation

Asthma is a chronic inflammatory disease of the airways marked by elevated type 2 inflammation (90, 91). ILC2 activity is implicated in airway inflammatory diseases (Figure 4C). ILC2-derived IL-13 is critical for inducing Th2 cell differentiation in response to allergic lung inflammation by promoting the migration of activated DCs to the draining lymph nodes, supporting the development of allergic adaptive immune responses (92). Circulating ILC2s from asthmatic patients produced more IL-5 and IL-13 in response to IL-25 and IL-33 stimulation relative to controls, and administration of prostaglandin D2, the ligand for CRTh2, promoted ILC2 accumulation in murine lungs (93, 94). A single nucleotide polymorphism resulting in elevated CRTh2 expression positively associates with asthma development in humans, although whether this corresponds directly to increased ILC2 presence is unknown (95). Interestingly, the prevalence of asthma is lower in adult males versus females, indicating sex-specific differences in type 2 immunity (96). Several animal studies recapitulated these sex-dependent changes in abundance, phenotype, and responsiveness of ILC2s and implicated the role of sex-hormones in facilitating sex-specific responses to alveolar diseases (96–100). For example, androgen-receptor signaling negatively regulated ILC2 cytokine secretion and differentiation and reduced IL-33-dependent lung inflammation in male mice (97, 100, 101).
Strikingly, neuronal and neuroendocrine-driven stimulation of ILC2s promotes allergic lung inflammation (102, 103). IL-5-stimulated nociceptor Nav1.8+ sensory neurons activated ILC2s through vasoactive intestinal peptide (VIP), while pulmonary neuroendocrine cells trigger ILC2s through the calcitonin gene-related peptide (CGRP) to promote allergic inflammation in the murine lung (102, 103). CGRP-secreting pulmonary neuroendocrine cells were increased in asthmatic patients suggesting that this mechanism could also support ILC2-mediated allergic inflammation in humans, inspiring several pathways of therapeutic interventions (103). Constitutive activation of ILC2s may lead to long-lasting alterations in the lung as found in other pulmonary diseases. For example, ILC2s are enriched in nasal polyps of chronic rhinosinusitis patients along with elevated IL5 and IL13 transcripts, suggesting an ILC2-dependent contribution to the disease-associated eosinophilia and chronic airway inflammation (104, 105). Polyp tissues identified with eosinophilia revealed a co-localization of ILC2s and eosinophils, indicating a possible cross-talk between IL-5-producing ILC2s and IL-4-producing eosinophils to support reciprocal activation and survival (106).

Complicating our understanding of ILC2s in allergic responses are recent findings from Golebsky and colleagues that ILC210sa are reduced in abundance in allergic individuals relative to non-allergic controls, while sublingual immunotherapy for grass pollen allergy restores this IL-10-producing subset which may confer protection and restoration of epithelial barrier integrity (16). Interestingly, murine lung ICOS’ST2+ ILC2s exhibit memory in response to allergen challenge dependent on ICOS and IL-33, marked by transcriptional and epigenetic programs involving the scaffold protein Four And A Half LIM Domains 2 (FHL2) (107). Further, adoptive transfer of FHL2’CRTIh2’ human ILC2s induced airway hyperreactivity in mice and were partially steroid resistant, suggesting memory ILC2s may be relevant to steroid-resistant asthma (107).

Similar to ILC2s, ILC3s have been linked to asthma pathology. IL-17 levels and IL-17” ILC3s were elevated in bronchial alveolar lavage fluid of asthmatic patients, especially in patients with severe disease (108, 109). An ILC3 gene signature was upregulated in nasal brushings of adult-onset severe asthma patients, while bronchial brushings revealed elevated type 2 related gene profiles, supporting the idea of an anatomic preference of distinct ILC responses that may selectively contribute to site-specific characteristics of disease (110).

ILCs also contribute to chronic pulmonary inflammation through regulation of adaptive immune cells. CD40L expression by human and murine T helper cells induces an IgE response by B cells, contributing to airway hyper-responsiveness (111, 112). CD40L expression on T cells is induced by cAMP only in the presence of CD56”CD16” NK cells through a contact-dependent manner to drive asthmatic IgE responses (112). In patients with severe asthma, NK cells expressed higher levels of CD69 and NKG2D in line with an activated phenotype. Despite higher activation status, NK cell ability to induce eosinophil apoptosis was impaired (113). IL-13 production by ILC2s was attenuated and NK cell-induced eosinophil apoptosis was greatly increased by lipoxin A4 (LXA4), a pro-resolving mediator negatively affected during severe allergic asthma (113, 114). Lacking efficiency in resolution of eosinophilic inflammation due to a lack of LXA4 production in severe asthma suggests another axis of interaction promoting pulmonary dysfunction of NK cell and ILC2 responses to inflammation (113). Collectively, multiple layers of regulation affect the localized activity and accumulation of ILCs in asthma, emphasizing the need to understand tissue signals that control ILCs to develop more targeted therapies.

**ILCs in COPD**

Chronic obstructive pulmonary disease (COPD) is an inflammatory condition characterized by permanent and progressive loss of lung function, associated with smoking and exposure to noxious stimuli (115). ILC1s are increased in abundance in COPD patient lungs, correlating with smoking status and symptom severity (116). All helper ILC subsets localized with lymphoid aggregates in COPD lungs (116). IL-17 upregulation in end-stage COPD is implicated in lymphoid follicle neogenesis, and De Grove et al. found trends of elevated abundance of NCR+ ILC3s and IL-17A+ and IL-22+ ILCs in the lungs of COPD patients (66, 117). While this seems to support the involvement of ILC3s in COPD, data supporting a specific role for ILC3-derived IL-17 is lacking. Co-culture of expanded human lung ILC3s with mesenchymal stromal cells induced upregulation of ICAM-1 and VCAM-1, suggestive of LTi activity, contrasting with observations in Rorc+ and Id2+ mice that develop lung lymphoid follicles even in the absence of ILC3s/LTis (118, 119). Interestingly, a subset of Neutropilin1+ ILC3s were recruited to high endothelial venules in lung tissues of smokers and COPD patients in a VEGF-A-dependent manner, although the specific role for ILC3s in COPD development and pathogenesis remains unresolved (118).

Circulating NK cells from smokers and COPD patients express higher levels of CD57 and have greater cytotoxicity against autologous lung epithelium than non-smokers or smokers without COPD (120, 121). The increase in cytotoxicity was mirrored in a murine COPD model after cigarette smoke exposure, demonstrating that trans-presentation of IL-15Rα by lung DCs was required to prime high NK cell cytotoxicity against autologous epithelial cells (120). Interestingly, cigarette smoke exposure induces a sustained loss of ST2 expression on ILC2s, dramatically reducing their responsiveness to IL-33, despite increased IL-33 production in severe COPD (122). Conversely, smoke induces an upregulation of ST2 on NK cells, leading to IL-33-mediated activation of NK cells instead of ILC2s, explaining the increase in type 1 immunity despite elevation of the type 2-activating cytokine IL-33 (122). Paralleling this, elevation of circulating ILC1s with a strong inverse correlation to ILC2 abundance was observed in COPD patients, further suggesting a misguided immune activation and cytokine-driven ILC plasticity, similar to mechanisms observed in the response to murine influenza infections (89, 106).
GATA3 and an upregulation of T-BET, increasing IFN-γ release while dampening IL-4 and IL-13 production (89, 106). These results collectively demonstrate that persistent lung inflammation and exposure to smoke leads to changes in the local ILC composition and function (Figure 4D).

**ILCs in the Skin**

The skin is a barrier organ that employs immunological, microbial, and physiochemical mechanisms to protect the body from pathogens and harmful environmental factors. The skin is composed of three distinct layers: the epidermis (mainly comprised of keratinocytes), the underlying dermis, and the innermost subcutis. Tissue-resident and long-lived ILC subsets comprised of keratinocytes, the underlying dermis, and the innermost subcutis. Tissue-resident and long-lived ILC subsets have been identified in mice and humans with varying proportions identified across studies (123–127). A more granular analysis of skin by layer revealed a predominant accumulation of ILC3s in the epidermis, ILC2s in the subcutis and comparable abundance of both subsets within the dermis in mice (128). This distribution has been attributed to the localized release of IL-7 and TSLP by either hair follicle keratinocytes or epithelial cells (128, 129). Mirroring murine models, human skin ILC2s can be activated by IL-25, IL-33, and TSLP, with high expression of IL-33 and TSLP during chronic skin inflammation (130–132).

ILCs regulate essential homeostatic functions of the skin (Figure 5A). For example, murine TNFαLTαβCCR6+ ILC3s negatively regulate the size of the lipid-secreting sebaceous glands, while the differentiation, proliferation, and expression of antimicrobial proteins by keratinocytes depends on IL-22 stimulation from ILC3s or epidermal T cells (128, 133). Mirroring murine models, human skin ILC2s can be activated by IL-25, IL-33, and TSLP, with high expression of IL-33 and TSLP during chronic skin inflammation (130–132).

ILCs in Wound Healing

ILCs directly influence skin repair after damage. Murine skin-resident ILC2s activated by IL-33 from injured epithelial cells proliferate at sites of injury while anti-CD90 depletion of ILC2s in Rag1–/– mice delays wound healing (135). CD4+NKp46low/ILC3s are recruited by damage-induced CXCL13 and CCL20 and promote wound closure via IL-17A, IL-17F and IL-22 and indirectly through CCL3-mediated macrophage recruitment (136). Comparable findings were observed in IL-22–/– mice, where deficiency in IL-22 impaired keratinocyte proliferation, impeding repair (137). These results support a role for ILC2s and ILC3s in regenerative remodeling of the skin, yet research is needed to translate animal findings to humans and to define the differential impacts of ILCs and T helper cells (138).

**ILCs in Psoriasis**

Psoriasis is a chronic inflammatory skin disease that manifests as red scaly plaques caused by hyperproliferation of keratinocytes downstream of excessive repair pathways (139). Elevated IL-17 levels and Th17-associated gene expression signatures are found in psoriatic lesions and mouse models, implicating IL-17 and IL-22 in pathogenesis (140–142). IL-22- and IL-17-producing NCR+ ILC3s and CD56+RORγt+ ILCs are enriched in inflamed and non-inflamed skin of psoriasis patients (143). Anti-TNF treatment reduced circulating ILC3s in patients, corresponding with a decrease in inflammatory lesions (124). Further, IL3-derived IL-22 induces an upregulation of MHC-II on keratinocytes, which promotes T cell polarization and skin inflammation, demonstrating a key circuit mediating skin inflammation (144). Skin ILCs are also capable of driving T cell activation directly by presenting lipid antigens in a CD1a-dependent manner, leading to local activation of T cells in response to dermal bacteria (145).

There is limited and sometimes conflicting evidence for the role of NK cells in psoriasis. Studies have indicated that circulating NK cells are reduced in psoriasis patients (146, 147), or that no change was observed compared to healthy controls (148, 149). Within psoriatic plaques, Ottaviani et al. observed CD56+CD16+ NK cells that co-expressed CD161, NKG2A, and CD69 (150). Supernatants from culturing these NK cells activated keratinocytes, increasing MHC-I, ICAM-1 and HLA-DR expression, along with CXCL10 and CCL5 secretion (150). These chemokines induced migration of skin-derived NK cells, supporting NK cell-keratinocyte cross-talk in psoriatic inflammation (150). NK cells appear to be hypofunctional in psoriasis, with reduced degranulation and IFN-γ potential (146, 149). The role of helper type 1 ILCs is even less defined, however expansion of ILC1s was observed in psoriatic lesions (126).

**ILCs in Atopic Dermatitis**

Atopic dermatitis (AD) is a common inflammatory skin disorder characterized by high levels of IL-4, IL-5 and IL-13 (151, 152). AD skin lesions are enriched for skin-resident ILC2s, which are activated by TSLP or IL-33, promoting type 2 inflammation, demonstrating a key circuit mediating skin inflammation (144). Skin ILC is also capable of driving T cell activation directly by presenting lipid antigens in a CD1a-dependent manner, leading to local activation of T cells in response to dermal bacteria (145). The role of helper type 1 ILCs is even less defined, however expansion of ILC1s was observed in psoriatic lesions (126).
Mack et al. found particularly reduced levels of circulating mature CD56dimCD16+ NK cells with high expression of KIRs and CD57 in patients with moderate-to-severe AD (152). A regulatory circuit between NK cells and ILC2s is supported by three lines of evidence: NK cell recovery occurring after IL-4 blockade; ILC2 accumulation in AD lesions of NK cell-deficient mice; and NK cell recovery and activation after IL-15 superagonist treatment leading to reduced ILC2 levels and disease scores in an AD model (152). Thus, cross-talk between ILC subsets may underlie the development and severity of AD (Figure 5B).

**ILCs IN THE INTESTINE**

The intestine is the largest mucosal surface in the human body and faces unique challenges. As a barrier surface, immune function in the intestine must balance tolerance and control of commensal microbes with protection from pathogens. Among immune residents of the intestine, ILCs have key roles in sustaining gut barrier integrity, repair, immune homeostasis, and host defense (Figure 6A). ILC distribution along the human intestine was reported by Simoni et al. and Yudanin et al. (67, 127). In line with observations made in mice, both groups demonstrated the presence of NK cells, ILC1s, ILC2s, and ILC3s across the intestinal tract, with predominance of ILC1s and ILC3s (67, 127, 157). NK cells are low in abundance and mainly CD56bright with distinct surface marker expression (64) (Figure 2). Intestinal ILC1s are heterogeneous, including a population of CD103+ ILC1s located in the epithelium, and CD127+ ILC1s residing in the lamina propria (LP) (158, 159). ILC3 subsets also localize within distinct microanatomical compartments of the gut epithelium/isolated lymphoid follicles (ILFs)/LP, but it remains to be shown if a similar distribution applies to humans (160, 161).
FIGURE 6 | ILCs in the intestines. ILCs have important roles in maintaining intestinal homeostasis (A). ILC2s can be activated by both IL-25-producing tuft cells or IL-33 and TSLP-secreting stromal cells to promote anti-parasitic immunity in the intestines. ILC2s secrete IL-5 and IL-13 to promote host defense through parasite expulsion. Similarly, microbiota-sensing CX3CR1+ macrophages position IL-22-secreting CXCR6+ NCR+ ILC3s in the lamina propria via CXCL16. IL-22 supports anti-microbial gene expression, promotes stem cell turnover, crypt proliferation, and DNA damage repair. Interaction of ILC3/LTia1b2 and LTBR on mesenchymal cells leads to the upregulation of VCAM-1 and ICAM-1, resulting in the formation of Peyer’s patches and ILF. These tertiary lymphoid structures support the differentiation of IgA-producing plasma cells to promote barrier defense and host-microbiota mutualism. Clock genes and circadian cycles, modulated through feeding and the microbiota drive important homeostatic neuro-immune interactions in the gut. Disruption of circadian regulation alters ILC3 function, abundance, and trafficking into the intestines while negatively regulating ILC2s through adrenergic signaling. Glucocorticoids or vasoactive intestinal peptide further control ILC1 and ILC2 responses. (B) In chronic inflammatory disease such as intestinal bowel disease (IBD), the inflamed gut induced TGF-β and Matrix metalloproteinase 9 production by ILC1s leading to the expansion of epithelial crypt cells and extracellular matrix deposition by fibroblasts, exacerbating fibrosis. In contrast, pro-tolerogenic ILC3 functions including the release of GM-CSF, IL-2 or the expression of MHC-II are impaired in IBD patients, suggesting an anti-inflammatory role for ILC3s. IL-10 producing regulatory ILC2s or ILCregs may also suppress intestinal inflammation. (C) Enteric infection by Rotavirus induces epithelial-derived IL-1α to promote ILC3 production of IL-22, which synergizes with epithelial IFN-λ to promote the induction of antiviral responses in intestinal epithelial cells. Created with Biorender.org.
Intestinal ILCs promote host immunity against pathogenic and commensal microbes through interactions with sentinel immune and tissue cells. For example, murine ILC2s activated by IL-25-producing tuft cells or IL-33- or TSLP-secreting stromal cells promote anti-parasitic immunity, while DC-derived IL-33 promotes regulatory T cell (Treg) responses, suppressing anti-parasitic immunity (4, 24, 162–164). Myeloid cells, especially CXCL16-producing CX3CR1⁺ macrophages are critical for sustaining lamina propria-resident CXCR6⁺ NCR⁺ ILC3s as a major source of IL-22 in the intestinal LP (160). These ILC3s support IL-22-dependent intestinal epithelial antimicrobial gene expression, stem cell turnover, crypt proliferation, and DNA damage repair (160, 165–168).

While ILC3-derived IL-22 protects the intestinal epithelium against genotoxic stress, risk-associated single nucleotide polymorphisms have been identified within IL22 and the IL-23 signaling pathways as a driver of colorectal cancer in patients (165, 169, 170). Nevertheless, ILC3-derived IL-22 and LTα alter positively the glycosylation activity of epithelial cells, supporting glycan-scavenging intestinal commensal microbes and balanced host-microbe interactions and providing protection from infection (171, 172). sLT, expressed by human and mouse LTis, is essential to initiate the development of cryptopatches (CPs) and ILFs in the gut (11, 173). These tertiary lymphoid tissues support the differentiation of IgA⁺ B cells, especially CXCL16-producing CX3CR1⁺ macrophages to promote barrier defense (174, 175). ILC3s as a major source of IL-22 in the intestinal LP (160). These ILC3s support IL-22-dependent intestinal epithelial anti-microbial gene expression, stem cell turnover, crypt proliferation, and DNA damage repair (160, 165–168).

Cholinergic neurons in the gut and lung of mice produce neuromedin U in response to helminth challenge, which stimulates IL22 proliferation and production of IL-4 and IL-13 in an IL-33-independent manner (192). The neuromedin U receptor does not appear to be expressed by other hematopoietic cells besides ILC2s at significant levels (192). In humans, the NMUR1 transcript was detected in intestinal ILC2s, yet direct evidence for this ILC2-neuronal interaction in humans is lacking (192). Other modalities where the nervous system regulates ILCs includes negative regulation of ILC2s by adrenergic signaling, glucocorticoid dampening of ILC1 and ILC2 responses, VIP stimulation of ILC2s, and ILC3 co-localization with neurons in enteric CPs, as detailed in a review by Klose and Artis (3). Interestingly, circadian light-dark cycles regulated neuron-immune interactions and intestinal ILC3-specific gene expression through diurnal oscillations of Rorc, Il17a, and Il22, while disruption of ILC3 circadian regulation altered their function, abundance, and trafficking in the murine intestine (2, 193–195). Interestingly, the gut microbiota contributed to control of this circuit, as antibiotic treatment partially restored ILC3 abundance and constrained cytokine production in circadian-disrupted mice (195). In mice, VIP promotes ILC3 intestinal recruitment and maintains expression of gut-homing receptor CCR9 (196). Talbot et al. reported a feeding-induced inhibition of ILC3s by VIPergic neurons, regulating mucosal immunity by dampening IL-22-induced antimicrobial peptide production in exchange for enhanced absorptive capacity of the intestinal epithelium marked by increased fatty acid transporter (Ffar2) expression (197). This contrasts with findings by Seillet et al. that VIP stimulation increased IL-22 production by enteric ILC3s, although the reason for these conflicting results is unclear, suggesting complex signals regulate intestinal ILC3 activity (198). Together, intestinal ILC3s are regulated by a complex circadian network involving light-dark cycles, microbial signals, and nutrient-driven neuronal regulation. Of note, the production of IL-5 by murine ILC2s was also circadian regulated (198).
expansion in inflamed intestinal tissue is location-specific, with
greater expansion of LP-resident CD127+ ILC1s versus
intraepithelial ILCs in Crohn’s disease (CD) patients (158, 159, 200, 201). Specific expansion of CD127+CD94+ Granulysin+ ILC3s is observed in the inflamed LP of CD
patients (202). With elevated secretion of TGF-β and MMP9,
mouse ILCs facilitate the expansion of CD44+ epithelial crypt
cells and extracellular matrix deposition by fibroblasts,
collectively supporting matrix remodelling and epithelial
proliferation that may exacerbate inflammation-associated
fibrosis (Figure 6B) (203). In contrast, ILC3 abundance and
homeostatic functions in circadian oscillation, production of IL-
2, and expression of MHC-II were critically impaired in IBD
patients, supporting anti-inflammatory contribution of ILC3s
(178, 180, 193, 195). ILC3 secretion of IL-22 is enhanced by G
Protein-Coupled Receptor 34 (GPR34) recognition of
lyso phosphatidylserine from apoptotic neutrophils, further
supporting a role of ILC3s in sensing intestinal injury and
initiating repair responses (204). However, ILC3s may
contribute to intestinal inflammation under permissive
circumstances (205). Further, destabilizing RORγt expression
promoted the differentiation of ILC3s into ILC1/ex-ILC3 in
mice and humans and correlated with intestinal IBD-like
inflammation (206, 207). Interestingly, this differentiation was
not static, but was regulated by the myeloid cytokine milieu in
the intestinal tract (159). Counterbalancing the elevated type 1
and type 3 immunity reported in IBD, ILC2-derived AREG was
sufficient to reduce DSS-induced damage in mice by promoting
epithelial integrity and mucin production (162). Bando et al.
further identified murine ILC2s as a dominant source of IL-10 in
the intestine, while Wang et al. identified a distinct subset of IL-
10-producing regulatory ILCs in humans and mice, supporting
that IL-10 producing ILC2s or ILCregs may suppress intestinal
inflammation (Figure 6B) (13, 17). Targeting ILC3-to-ILC1
plasticity, ILC1 activation, and ILC3 abundance may be a
promising approach to restore intestinal immune homeostasis
under chronic inflammatory conditions (208–211).

**Gastrointestinal Infection**

ILCs play a critical role in the response to intestinal pathogens in
humans, highlighted by cases of deficiency in RORC resulting in
severe mucosal fungal and bacterial infections (212). Along this
line, susceptibility to infections by enteric extracellular pathogens
are increased in the absence of IL-22 or GM-CSF, highlighting a
critical role for ILC3-associated cytokines in barrier defense
(213–216). Mouse ILC3s and ILC1s/ex-ILC3s promote antimicrobial responses via surface lymphotixin-mediated
differentiation of goblet cells and IFN-γ-induced production of
mucons, further emphasizing the synergistic actions of ILC1s and
ILC3s that require underlying microbial recognition and
activation by myeloid cells (207, 217–219). Whether this
permits discrimination of commensal and pathogenic microbes
requires further investigation (219). In response to mouse enteric
rotavirus infections, epithelial IL-1α induced ILC3-derived IL-22
which synergized with epithelial IFN-λ, promoting the induction of
antiviral gene expression in intestinal epithelial cells, limiting
viral replication and tissue damage (Figure 6C) (220). While
ILC3s can promote antiviral immunity, they experience
cytokine-dependent depletion in the intestinal tract of HIV+
human and SIV+ non-human primates, altering epithelial
permeability and homeostasis (221–223). Collectively, ILCs
promote intestinal barrier defense against enteric bacterial,
fungal, and viral infections by exerting cytokine or cell contact-
dependent effects on intestinal epithelial cells.

Enteric parasites and worms constitute a major global health
burden. Murine NK cell recruitment to the intestine early after
helminth infection does not affect parasite burden but limits the
tissue damage induced by infection (224). Experimental models of
worm infections revealed the importance of ILC2s and ILC2-
derived cytokines in intestinal host defense in mice (225–227).
For example, IL-13 from murine ILC2s promoted tuft and goblet
cell differentiation from crypt progenitors, contributing to
epithelial remodeling and worm expulsion in the characteristic
“weep and sweep” response (4, 228). ILC2s actively promoted Th2 cell responses via MHC-II and co-stimulatory molecules,
partially acquired through trogocytosis, while T cell-derived IL-2
activated ILC2s for efficient helminth expulsion in mice (229).
Further, ILC2s are activated by acetylcholine and upregulate
ChAT to produce acetylcholine in response to helminth
infection, supporting efficient helminth expulsion through a
potential autocrine signaling mechanism (230). The activation
of ILC2s following worm infection could be blunted through
parasite-derived, bio-active components interfering with the IL-
33-ST2 axis (231). Intriguingly, helminth infection changed the
global distribution and activation of murine ILC2s through the
induction of S1PR1-dependent egress of gut ILC2s and
accumulation in the lungs, suggesting a coordinated response
to protect distal body sites targeted by helminth infection
(72, 232).

While the fetal and adult human intestine hosts a population of
ILC2s capable of releasing type 2 cytokines following stimulation
with IL-2, IL-25, and IL-33, their role during human parasitic
infections has not been well detailed (104). Lack of sample
availability has hampered investigation of intestinal ILC
abundance and function of worm infected patients (233).
To date only two studies analyzed ILCs in worm infected patients.
Nausch et al. observed a reduced frequency of ILC2s in children
infected with Schistosoma, while Boyd et al. observed an increase
in circulating c-kit+ ILCs and elevated IL-13 secretion in adult
patients with filarial infections, suggesting heterogeneity in ILC
responses dependent on age and/or helminth species (234, 235).

Collectively, intestinal ILCs support host immunity, barrier
defense and tissue repair during infection and homeostasis, but
also may perpetuate inflammation under permissive
microenvironmental conditions.

**ILC3s IN THE LIVER**

The liver is critical for metabolism and blood detoxification. Constant exposure to an array of antigens and microbial
products within liver sinusoids promotes tolerance to
predominantly harmless antigens (236, 237). The liver contains
a large proportion of innate immune cells such as Kupffer cells
NK cells in Viral Hepatitis

NK cells are implicated in both Hepatitis C (HCV) and Hepatitis B (HBV) infections, which are major causes of liver inflammation and cirrhosis, leading to development of hepatocellular carcinoma (248) (Figure 7A). Peripheral NK cell abundance is reduced in both HCV- and HBV-infected patients, with reduced IFN-γ and TNF-α potential particularly in HBV, suggesting functional dysregulation (249). Cytotoxic impairment is associated with chronic infection establishment, while acute HCV infection induces NK cell activation, including increased NKG2D expression and greater capacity for cytotoxicity and IFN-γ production (250). Despite shared dysregulation, NK cell phenotype differs between chronic HBV and HCV; an enrichment of NKG2C+ NK cells are observed in HBV, whereas increased CD69 expression and decreased inhibitory KIR expression are observed in HCV (249). Differences in NK cell KIR and HLA allele expression may differentiate infections that are self-limited versus those that become chronic; KIR2DL3 and HLA-C1 expression is reported to be protective in HCV infection (251, 252). Weaker inhibitory signals by HLA-C1 may allow for increased NK cell activation and viral clearance (251, 252). In agreement, degranulation marker CD107a was increased on NK cells with KIR2DL2/3 and was highest in those with self-limiting infections (250). Engagement of HLA-E with elevated NKG2A and CD94 receptors on NK cells of HCV-infected individuals results in TGF-β and IL-10 production and impaired ability to activate DCs for virus-specific T cell responses, in line with findings that hepatocyte and Kupffer cell HLA-E expression correlates with HCV severity (253, 254). Of note, intrahepatic CD56+ CD16− NK cell abundance correlates with better liver function and lower disease scores in HCV-positive patients undergoing liver transplantation (255).

In chronic HBV, circulating and intrahepatic NK cells highly express TRAIL and CD69, especially the CD56+ subset (256). Elevated IFN-α and IL-8 upregulate TRAIL expression on NK cells and TRAIL-R2 expression on hepatocytes, respectively, suggesting TRAIL-dependent targeting of hepatocytes by CD56+ NK cells mediates damage during chronic HBV flares (256). Notably, HBV-specific T cells also have high expression of TRAIL-R2 and are susceptible to targeting by NK cells, supporting a role for NK cells in regulating anti-HBV T cell responses (257).

Comparatively little is known about the role of human hILCs in hepatitis infections. Increased hILCs were reported in the circulation of patients with chronic HBV (258, 259). HBV-related cirrhosis progression correlated with IL-17A and IL-22 production by ILC3s, suggesting ILC3 promotion of fibrosis, likely in part due to IL-22-mediated suppression of anti-fibrotic IFN-γ (Figure 7A) (259). While HCV/HBV do not infect mice, other viral hepatitis models provide some context into ILC viral responses in the liver more generally. Hepatic ILC3s produce IL-17A/F alongside IL-5 and IL-13 dominant responses by ILC2s are unknown. Interestingly, type 2 immunity, with an implication for ILC2 activity (262). Hepatic stellate cells become activated and transdifferentiate into myofibroblasts that produce copious extracellular matrix proteins, driving fibrosis and loss of function resulting in cirrhosis (263). Patients with cirrhosis have elevated serum IL-33 and increased intrahepatic ILC2s, function resulting in cirrhosis (263). Patients with cirrhosis have elevated serum IL-33 and increased intrahepatic ILC2s, increasing T cell fibrosis,

ILCs in Liver Fibrosis

Liver disease is characterized by fibrogenesis of the liver, driven by type 2 immunity, with an implication for ILC2 activity (262). Hepatic stellate cells become activated and transdifferentiate into myofibroblasts that produce copious extracellular matrix proteins, driving fibrosis and loss of function resulting in cirrhosis (263). Patients with cirrhosis have elevated serum IL-33 and increased intrahepatic ILC2s, correlating with disease severity (247, 264, 265). Expansion of ILC2s and activation by IL-33 from damaged parenchymal cells results in IL-13 production driving fibrotic gene expression in hepatic stellate cells in fibrosis models, or IL-5 production with resultant hepatic inflammation and eosinophilia in immune-mediated hepatitis models (265, 266). While both effects are IL-13-dependent, additional signals which influence IL-5 versus IL-13 dominant responses by ILC2s are unknown. Interestingly, liver ILC2s present antigen to CD4+ T cells which produce IL-2 to sustain ILC2 expansion (267). High levels of IL-6, linked to liver regeneration, were produced by IL-33-activated liver ILC2s.
FIGURE 7 | ILCs in the liver. The liver is occupied by a variety of ILCs that play diverse roles in viral hepatitis, liver disease, liver cirrhosis, and liver regeneration and repair. (A) Hepatitis C (HCV) and Hepatitis B (HBV) are key inducers of liver inflammation and cirrhosis and lead to the development of hepatocellular carcinoma. The abundance of NK cells in the blood of both HBV/HCV infected patients is reduced, suggesting elevated homing to the liver where functional deficiencies like impaired IFN-γ and TNF-α production are reported. NK cells in chronic HBV and HCV infected patients adopt distinct phenotypes that manifest in an enrichment of NKG2C-expressing NK cells or altered CD69 and inhibitory KIR expression. In contrast, acute HCV infection promotes elevated NKG2D and IFN-γ expression while IFN-γ is reduced in chronic infections. HCV-infected hepatocytes and Kupffer cells express higher levels of HLA-E that boost TGF-B and IL-10 production by NK cells through NKG2A and CD94. CD56bright NK cells in chronic HBV infection facilitate TRAIL-dependent hepatocyte death. ILC3s separately support hepatic stellate cell expansion and counteract IFN-γ. (B) In liver disease, ILC2 are increased and activated, driving liver fibrosis via AREG and IL-13. Similarly, in immune-mediated hepatitis, ILC2s are expanded and produced high levels of IL-5, recruiting eosinophils, and driving inflammation. (C) In liver cirrhosis, crosstalk between NK cells and CD8 T cells through the CD137-CD137L axis enhanced cytotoxicity of NK cells against HSCs. Alcohol exacerbates fibrosis chronically, but also attenuates NK-mediated cell killing, and reduced NKG2D, TRAIL and IFN-γ expression on NK cells. (D) NK cells upregulated TIGIT while hepatocytes upregulated the ligand PVR/CD155, attenuating IFN-γ production and promoting liver regeneration. Finally, extracellular ATP is elevated after liver injury and regulates regeneration in the liver via Nkp46+ NK cells. Created with Biorender.org.
indicating that ILC2s may have a dual roles in immune-mediated liver disease (267).

Intrahepatic human CD49a⁺ NK cells are expanded in cirrhotic livers (268). CD49a⁺CD25⁺ NK cells positively correlate with serum alanine aminotransferase, linking CD49a⁺CD25⁺ NK cells to liver inflammation (268). Conversely, liver NK cells dampen fibrosis by killing activated hepatic stellate cells in an NKG2D- and TRAIL-dependent manner, while IFN-γ reduces hepatic stellate cell activation and matrix protein deposition (269, 270). CD137-CD137L crosstalk between NK cells and γδ T cells enhances NK cell cytotoxicity (Figure 7C) (271). Chronic alcohol consumption exacerbates fibrosis, and ethanol attenuates NK cell cytotoxicity towards hepatic stellate cells by reducing NKG2D, TRAIL, and IFN-γ expression, suggesting immunological and environmental mechanisms of NK cell regulation (272).

**ILCs in Non-Alcoholic Liver Disease**

Non-alcoholic fatty liver disease (NAFLD) is the most common non-infectious chronic liver disease and can develop into non-alcoholic steatohepatitis (NASH) and progress to cirrhosis (273). NK cells are elevated in liver biopsies of NAFLD and NASH patients, with greater than two times increased NK cell abundance in NASH compared to NAFLD (274). NKG2D and TRAIL-DR5 transcript levels also have higher expression in NASH (274). Upregulation of MIC-A/B positively correlates with disease score and degree of fibrosis, suggesting NK cell engagement with MIC-A/B stress ligands could be a key factor in NASH development (274). In agreement, circulating NK cells from NASH patients had higher NKG2D expression (275). Depletion of IFN-γ-producing NKp46⁺DX5⁺ NK cells in a NASH mouse model altered macrophage phenotype, suggesting that IFN-γ from NK cells reduces fibrosis by polarizing macrophages away from a TGF-β pro-fibrotic phenotype (276). Additional studies are required to delineate the mechanisms that control whether NK cells limit or promote fibrosis.

While fewer studies have focused on hILCs, ILC3s appear to mitigate NAFLD. High fat diet increases ILC3 abundance in mice, while deficiency of ILC3s leads to liver fibrosis and an increase of pro-inflammatory gene expression with concomitant accumulation of saturated fatty acids (277).

**ILCs in Liver Regeneration and Repair**

The liver is uniquely capable of self-regeneration, including regenerating entire lobes after resection. Group 1 ILCs interact with injured tissue and influence regenerative capacity (Figure 7D). In models where NK cells are pre-activated by viral infection or TLR3 agonism to produce higher levels of IFN-γ, as well as in aged livers that have elevated IFN-γ signaling, regeneration is impaired (278, 279). NK cells upregulate T cell immunoreceptor with Ig and ITIM domains (TIGIT) while hepatocytes upregulate the ligand PVR/CD155, attenuating IFN-γ production and promoting liver regeneration (280). Mouse NKp46⁺ cells co-localized with F4/80⁺ cells in liver sinusoids, and NKG2D blockade abrogated regeneration, suggesting NKG2D-mediated crosstalk with Kupffer cells regulates regeneration (281). Extracellular ATP is elevated after injury and regulates liver regeneration (281, 282). ATP limits NK cell cytotoxicity while antagonism of ATP-receptor P2X1 reduces IL-22 production by group 1 ILCs in a murine liver resection model, resulting in dampered hepatocyte proliferation and elevated hepatocellular injury and stress (281, 283). Taken together, extracellular ATP released after resection may dampen NK cell cytotoxicity and promote IL-22 production to modulate time-dependent group 1 ILC functions supporting liver regeneration. Future studies that characterize marker expression in greater detail may clarify whether the cells identified were also inclusive of CD56⁺ ILC3s or were NK cells or ILC1s that converted to ILC3s.

**ILCs in Ischemia-Reperfusion Injury**

IRI occurs when temporary disruptions in blood flow cause hypoxic stress and injury to the kidney. Several lines of evidence suggest that ILCs influence IRI severity. Anti-asialo-GM1 and anti-NK1.1 depletion, or NKG2D blockade ameliorated IRI and prevented killing of Rae-1-expressing tubular epithelial cells by NK cells in mice (289, 290). Interactions between co-stimulatory receptor 4-IBB on NK cells and its activating ligand 4-1BBL on epithelial cells activate NK cells and recruit neutrophils via epithelial cell-derived CXCL1 and CXCL2 (291). Together,
these results support a role for NK cell-epithelial cell interactions in aggravating IRI.

IL-25 and IL-33 administration expands ILC2s in mice, attenuating IRI and promoting recovery post ischemic injury (292, 293). ILC2 depletion using anti-CD90 treated Rag1--/ mice abolished the protective effect of IL-33 administration (293). Further, adoptive transfer of either murine (into C57BL/6) or human ILC2s (into NSG (NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ) mice) conferred protection from IRI, while AREG-deficient ILC2s failed to abrogate IRI (293). In contrast, Liang et al. reported IL-33 treatment worsened disease scores and fibrosis in mice post-IRI (294). The timing and duration of IL-33 administration and experimental endpoints may account for differences in results, specifically that prolonged IL-33 administration may be detrimental, underscoring the importance of balance between tissue repair and fibrosis processes required to achieve tissue homeostasis.

Despite evidence that expansion or adoptive transfer of ILC2s is beneficial, depletion of ILC2s did not negatively impact IRI, as mice with reduced (Rorafl/fl Il7rcre/+), depleted (Icosdtr/+ Cd4cre/+), or deficient for ILC2s (Rorafl/fl Il7rcre/cre/+), had no effect on IRI, suggesting ILC2 functions can be compensated for by other cell types (295). A regulatory ILC population (Lin- CD127+ CD25+ IL-10+) was identified in mice that limited ILC1s and pro-inflammatory macrophages in an IL-10- and TGF-β-dependent manner (15). Reduced tissue damage was noted in experimental IRI when these cells were expanded in Rag-/- mice (15). Notably, endogenous ILCregs in IRI produced less IL-10 than expanded ILCregs, suggesting that endogenous ILCreg function is impaired in IRI. While the human counterpart of this regulatory ILC subset was identified, confirmation of their function is needed (15).

ILCs in Lupus Nephritis

ILCs have been linked to kidney autoimmune pathologies such as lupus nephritis (LN), a manifestation of systemic lupus erythematosus (SLE). Arai et al. identified two distinct NK cell populations within LN kidney tissue by scRNAseq, annotated as CD56dimCD16+ NK cells and tissue-resident CD56brightCD16- NK cells (296). CD56+ NK cells from SLE patients show an impaired antibody-dependent cellular cytotoxicity due to reduced CD3ζ signaling upon NCR engagement (297). Altered abundance of...
circulating ILCs in LN is associated with disease severity, with increased ILC1s across disease scores and decreased ILC3s in moderate to severe disease scores (298, 299). Further, reduced cytokine production and increased PD-1 expression suggest an exhausted ILC state in active disease (299). Specifically, CD117+ ILCs, likely ILC progenitors, were markedly decreased in LN and preferentially differentiated into ILC1s when cultured in LN plasma. Blockade of IL-1R reversed this effect, suggesting IL-1β-mediated regulation of the ILC progenitor pool (299). In a murine model of LN, renal ILC3s were the dominant source of IL-22 and were increased in abundance, while IL-22 deficiency ameliorated disease, supporting a pathogenic role for ILC3s in LN, yet whether an analogous mechanism applies to humans is unknown (300). These studies collectively support dysregulation of ILCs in SLE and LN.

ILCs in Pregnancy

Pregnancy is a unique case where non-self is protected from immune-mediated rejection. Dynamic changes occur in both maternal and fetal tissues as pregnancy progresses. The uterine mucosa undergoes cyclic remodeling, termed decidualization, in which the endometrium thickens in preparation for implantation (302). For implantation and placentation to occur, the decidua must be invaded by fetal tissue (trophoblast cells) (303). Together, maternal and fetal tissue interactions promote successful implantation, placentation, and arterial spiralization to facilitate blood and nutrient supply to the developing fetus (303).

Uterine NK (uNK) cells are important cellular regulators of fetal implantation and protect against maternal rejection of the fetus. These uNK cells are the most abundant leukocytes present in the uterine mucosa and exhibit differential functions and limited cytotoxicity compared to cNK cells (304). Despite the discovery of uNK cells in the early 1990’s, the function of uNK cells in healthy and abnormal pregnancy is still the subject of intense research. Uterine NK cells contribute to placental remodeling, striking a balance between excessive trophoblast infiltration and defective placentation, regulated by KIR and MHC-I interactions (305). In general, activating receptor ligation improves reproductive success by promoting trophoblast invasion and vascular transformation (306). Human chorionic gonadotropin (hCG) released by the implanting fetal trophoblast induces uNK cell proliferation through hCG N-linked carbohydrate recognition by CD206 (mannose receptor) on uNK cells, establishing a pathway of uNK cell regulation by the implanting embryo (307).

ScRNAseq defined three distinct subsets of decidual NK cells (dNK cells) in humans. All subsets expressed CD49A and CD9, dNK1 cells expressed CD39, CYP26A1 and B4GALT1, dNK2 cells expressed ANXA1 and ITGB2, and dNK3 cells expressed ITGB2, CD160, KLRC1 and CD103 (308). In particular, the highly granular and metabolically active dNK1 cells are hypothesized to interact with extravillous trophoblast cells because of high-level expression of KIRs and other HLA-molecule receptors (308). Unlike dNK2 and dNK3 cells, dNK1 cells were mostly IFN-γ in response to stimulation (309). Computational predictions suggest the mechanism behind the prevention of an inflammatory immune response relies on immune-tissue crosstalk (308). Decidual stromal cells highly express LGALS9 and CLEC2D, pointing to potential NK cell inhibition via interaction with TIM-3 and KLRC1 (308). In line with the scRNAseq findings, Huhn et al. confirmed three subsets of dNK cells by mass cytometry with differential expression of the transcription factors TBET and EOMES (309). NK cells in the uterus or decidua acquire KIRs and CD39 along a developmental trajectory, corresponding to increased immunomodulatory and angiogenic function (310). With KIR acquisition, dNK cell expression of LGALR1, Ki-67, Nkp30, and Granzyme B increased while NKG2D, CD161, and TBET decreased, unlike the relatively stable expression of these markers on cNK cells (309). Once acquired, the expression of KIRs remain remarkably stable for successive menstruation cycles (311). In another departure from cNK cells, granules were ~3 times larger in dNK cells and as KIR expression increased, degranulation and cytokine production decreased, supporting that dNK cells are phenotypically and functionally unique (309).

High NKG2C marks uNK cells that have acquired memory, or “trained immunity”, contributing to improved reproductive success in subsequent pregnancies by improving vascularization and placentation (312, 313). Greater abundance of uNK cells and aberrant function resulting in higher expression of angiogenic factors in the endometrium coincides with thickening of the spiral artery walls, suggesting alteration of uNK-mediated vascular remodelling as cause for recurring miscarriage (314, 315). However, lower abundance of uNK cells is also associated with recurrent pregnancy losses through reduced decidual-uNK cell interactions. Chronic senescence of decidual cells leads to tissue dysfunction not conducive to successful pregnancies and uNK cells selectively eliminate senescent decidual cells via NKG2D, while differentiating decidual cells support and recruit uNK cells with CXCL14, IL-15 and TIMP3 (316, 317). Indeed, endometrial biopsies from patients with recurrent pregnancy loss exhibit excessive decidual senescence and reduced uNK cell abundance, indicating that a balanced cooperation between decidual cells and uNK cells promotes healthy pregnancies (316).

dNK cells also protect against pregnancy loss from trophoblast bacterial infection. Here, rather than forming a cytotoxic synapse, dNK cells transfer granulysin to infected trophoblasts using nanotube connections, killing the intracellular bacteria without killing the trophoblast (318).
This pathway could account for NK-mediated host defense in a setting that aims to avoid excessive tissue damage.

Other ILCs also have defined roles in pregnancy and reproductive conditions. Vacca et al. reported ILC3s in human decidua express PD-1 and TIM-3, which regulate ILC3 cytokine production, most notably IL-22 (319). Since trophoblast cells are PD-L1 high, ILC3-trophoblast interactions may promote fetal tolerance during the first trimester (319). In support of this, PD-L1 levels were much lower or nonexistent in the trophoblast cells of spontaneous abortions compared to healthy terminated pregnancies. Subsets of CD127 hiCD117 hiAhR hiCD94 -CD56 +/-NKp44 +/- decidual ILC3s were capable of producing GM-CSF, XCL1, and low levels of IFN-γ upon stimulation (309). NCR+ILC3s correlate with neutrophil abundance in the

---

**FIGURE 9** | ILCs in the reproductive system. Most ILC data focuses on the female reproductive tract, where NK cells have established roles in pregnancy (A). uNK cells are regulated by human chorionic gonadotropin (hCG) released by fetal trophoblasts, signaling through CD206 (mannose receptor) to facilitate placental remodeling. Women with recurrent pregnancy losses show an increase in uNK cells in the endometrium, coinciding with thickened spiral artery walls and the resulting vascular remodeling affecting the blood flow to the fetus. In support of this, uNK cells from women with recurrent miscarriages also produced more angiogenic factors, fibroblast growth factors, and vascular endothelial growth factors. A special subset of memory uNK cells expressing higher levels of NKG2C contribute to improved reproductive success and lower incidence of pregnancy complications in subsequent pregnancies. In the human decidua, ILC3s express PD-1 and TIM-3, regulating ILC3 cytokine production, in particular IL-33. ILC3-trophoblast interactions may promote fetal tolerance during the first trimester via PD-1: PDL-1 interactions, supported by lower PD-L1 levels in trophoblasts of spontaneous abortions compared to healthy terminated pregnancies. (B) Reduced stem cell factor leads to a higher proportion of immature uNK cells in endometriosis, potentially contributing to infertility associated with endometriosis. (C) In a model of PCOS, microbial dysregulation led to reduced bile acids needed to support ILC3 function. The reduced ILC3 abundance and IL-22 production led to cystic follicle development and insulin resistance. Created with Biorender.org.
human decidua and produce GM-CSF and CXCL8, supporting neutrophil recruitment and survival (320). Based on lower decidual neutrophil numbers in patients with miscarriages, Croxatto et al. hypothesize that the ILC3-neutrophil axis is beneficial, particularly in early stages of pregnancy (320).

ILCs in Endometriosis

Pathological functions of uNK cells are linked to endometriosis, a condition affecting ~10% of women where endometrial tissue grows outside of the uterus, resulting in debilitating pain and infertility. Patients with endometriosis have increased immature uNK cell counts and lower levels of stem cell factor (SCF) in the endometrial tissue, associated with infertility (Figure 9B) (321). Supplementing cultures of immature uNK cells with SCF supports uNK cell maturation (321). Endometrial stromal cells express high levels of SCF, suggesting stromal-uNK cell interactions influence fertility outcomes in endometriosis. SCF receptor expression is also found on helper ILCs, however, their role in endometriosis requires further investigation (322–324). While many questions remain, these reports support a critical role for uNK cell homeostasis in fertility.

Notably, IL-33 elevation is implicated in endometriosis and exogenous IL-33 exacerbates lesion severity and fibrosis dependent on ILC2s in a murine endometriosis model (325). Yet, in endometrial tissue of patients with endometriosis, ILC2s and ILC3s are reduced in abundance relative to non-endometriosis controls (326). Further work will be needed to clarify the role of hILCs in endometriosis.

ILCs in Polycystic Ovary Syndrome

Separate from protective roles in pregnancy, reduced ILC3 activity is associated with polycystic ovary syndrome (PCOS). PCOS encompasses mixed metabolic and reproductive pathologies, such as irregular ovulation, infertility, hyperandrogenism, insulin resistance, and adipose tissue inflammation associated with a complex etiology including hormonal dysregulation and heritability (327). Reductions in bile acids due to microbial dysregulation decreased IL-22 production by ILC3s and promoted insulin resistance and cystic follicle development in a murine PCOS model (328). This was reversed by supplementing missing bile acids or IL-22, supporting a link between the gut and fertility (328). However, hormonal imbalances impact ILC function in PCOS. For example, progesterone driven IL-15, IL-18 and CXCL10 expression promote uNK cell recruitment and proliferation, and are altered in PCOS endometrial tissue (Figure 9C) (329). These findings indicate that tissue-ILC and microbiota-ILC interactions critically regulate reproductive homeostasis on multiple levels.

ILCs in the Heart

In mice, NK cells account for ~3% of cardiac immune cells, ILC2s for ~1.7%, and ILC1s for 0.2%, while ILC3 abundance is negligible (330). Compared to lung ILCs, murine cardiac ILC2s had lower expression of ICOS, CD25, and Ki-67, and higher expression of Sca-1 and GATA3 (330). Only 2% of cardiac ILC2s in mouse were donor-derived after 2 months of parabiosis, indicating that ILC2s are a stable tissue-resident population in the heart (330). Cardiac-resident ILC2s respond to IL-33 but not IL-25, and a committed cardiac ILC2 precursor (ILC2p) in mice and humans exists in a quiescent state with the capability to differentiate into ILC2s in response to myocardial infarct or myocarditis (331). The existence of undifferentiated ILC2p within tissues has been observed before and suggests a role for this pool of precursors as a reservoir for ILCs to protect from tissue damage (332). Cardiac ILC activity has been implicated in several disease models (Figure 10).

ILCs in Atherosclerosis and Coronary Artery Disease

Conflicting findings on ILC subset functions in atherosclerosis and coronary artery disease (CAD) have been reported. Selathurai et al. found murine NK cells were detrimental to atherosclerotic disease, increasing lesion size in a Perforin- and Granzyme B-dependent manner, while Nour-Eldine et al. found no effect of NK cells on lesion development using a distinct genetic depletion model, likely accounting for divergent findings (333, 334).

In humans, a study of acute ST-segment elevation myocardial infarction (STEMI) found elevated circulating ILC1s within 12 hours of symptom onset which produced more IL-12, IL-18, IFN-γ, and TNF-α, and were associated with a higher risk of major adverse cardiovascular events (335). In contrast, NK cells were reduced and have lower cytotoxicity in CAD patients, both in the case of stable angina and incidence of myocardial infarction or unstable disease (336–338). During follow-up, patients who failed to reconstitute their peripheral NK cells post myocardial infarction had higher levels of serum IL-6 and exhibited characteristics of metabolic syndrome, suggesting poor NK cell recovery corresponds with low-grade inflammation (336). Recovery of NK cells in CAD patients is potentially self-regulated, as apoptotic NK cells both respond to and produce FasL, which is elevated in serum and correlates with NK cell levels and apoptotic susceptibility (339). Increased proportions of CD56bright NK cells were identified in carotid plaques compared to autologous peripheral blood, and greater NK cell infiltration corresponded with symptomatic versus asymptomatic CAD patients (340). Soluble B7-H6 levels of 250 pg/ml were detected in symptomatic patients but not in asymptomatic patients or healthy controls (340). Notably, B7-H6 can interact with NKp30, yet further studies are needed to directly assess B7-H6 and NK cell interactions in this context. Circulating NK cells from atherosclerotic patients had higher TIM-3 expression than healthy controls, with the greatest levels in those with unstable plaques (341). TIM-3 blockade reduced the death of NK cells cultured in TNF-α, suggesting that TIM-3 promotes cytokine-induced NK cell apoptosis in atherosclerosis (341). Whether NK cells are preferentially recruited to unstable carotid plaques, or functionally contribute to plaque destabilization requires additional study (340).

ILC2s appear to have cardioprotective functions based on mouse models. ILC2s protect from cardiac fibrosis and are enhanced by exogenous IL-33, producing AREG and BMP-7 to support cardioprotective responses to injury (342). Expansion of
ILC2s reduces atherosclerosis severity and lesion size, while genetic ablation (Staggerer/Rora Flox−CD127 Cre) exacerbates disease (343, 344). Notably, protection is IL-5 and IL-13-dependent, recruiting eosinophils and polarizing macrophages towards an anti-inflammatory phenotype (342, 343). Further, pericardial and cardiac ILC2s expand early post-experimental myocardial infarction, peaking at day 3 before returning to homeostatic levels, while the absence of ILC2s impairs cardiac remodeling and results in larger areas of scarring (345). Together, this supports a role for cardiac-resident ILC2s in directing repair pathways in response to injury.

### ILCs in Cardiac Inflammation

ILC expansion has been observed in patients with pericarditis (346). In contrast to cardioprotective findings above, ILC2s have been implicated in pericarditis pathology. Exogenous IL-33 expanded murine pericardial ILC2s, driving cardiac fibroblasts to secrete CCL11/eotaxin, leading to the accumulation of eosinophils. In humans, CD127+ ILCs increase in the pericardial fluid during cardiac disease, particularly during pericarditis. Separately, the expansion of ILC2s by IL-33 was cardioprotective after injury, reducing fibrosis. Within 12 hours of acute ST-segment elevation myocardial infarction (STEMI), ILC1 elevation peaks. Higher ILC1-associated IL-12, IL-18, IFN-γ, and TNF-α levels lead to a higher risk of major adverse cardiovascular events.

---

**FIGURE 10** | ILCs in the heart. Limited studies have examined ILCs in the heart. In mice, IL-33 administration or CD27+Sca-1+ fibroblast-derived IL-33 expands ILC2s in the pericardium, driving cardiac fibroblasts to secrete CCL-11/eotaxin, leading to the accumulation of eosinophils. In humans, CD127+ ILCs increase in the pericardial fluid during cardiac disease, particularly during pericarditis. Separately, the expansion of ILC2s by IL-33 was cardioprotective after injury, reducing fibrosis. Within 12 hours of acute ST-segment elevation myocardial infarction (STEMI), ILC1 elevation peaks. Higher ILC1-associated IL-12, IL-18, IFN-γ, and TNF-α levels lead to a higher risk of major adverse cardiovascular events. Created with Biorender.org.

---

ADIPOSE ILCs

Adipocytes are critical regulators of energy and glucose homeostasis. They are a heterogeneous population of cells, comprising energy-storing white adipocytes, thermogenic...
brown adipocytes that express uncoupling protein-1 (UCP-1) to dissipate energy as heat, as well as beige adipocytes that reside within white adipose tissue (WAT) and upregulate UCP-1 in response to environmental cues (349). Beige adipocyte accumulation protects from insulin resistance, and regulation of the beiging process has become an attractive therapeutic target for metabolic dysregulation and type 2 diabetes (350).

ILC2s are the dominant hILC subtype identified in adipose tissue, with phenotypic variation across different murine adipose compartments: ILC2s in para-aortic adipose tissue have an inflammatory phenotype defined by IL-25 responsiveness and high KLRG1 expression, whereas peri-gonadal adipose ILC2s are IL-33 responsive, expressing ST2 (343, 351). Intriguingly, mouse ILC2s highly express bone morphogenetic protein (Bmp)2 and Bmp7, which promote adipocyte differentiation, while ILC-deficient mice have more CD34+PDGERα+ precursor adipocytes, supporting a role for ILCs in adipogenesis (352). Under homeostatic conditions, ILC2s orchestrate immune responses in adipose tissues by recruiting eosinophils, promoting alternative activation of macrophages, and regulating beiging, glucose catabolism, and insulin sensitivity in adipose tissues (Figure 11A) (353, 354). In support of this, depletion of IL-5 and IL-13-producing cells (mainly ILC2s) corresponded to a reduction of eosinophils and Arg-1+ adipose macrophages in visceral adipose tissue (355). ILC2s also promote Treg responses through ICOSL and OX40L co-stimulation in adipose tissues, critical for supporting insulin sensitivity (356–358).

Mouse studies support that ILC2s can directly promote adipose beiging, supporting homeostasis and preventing obesity (5, 359, 360). ILC2s are sustained by IL-33 from adipose stem and progenitor cells (ASPCs) (360). Stromal ICAM-1 interactions with LFA-1 on ILC2s promotes ILC2 activation and proliferation in adipose tissue, while IL-4/IL-13 expression by ILC2s induces eotaxin (CCL11) expression in stromal cells, supporting eosinophil recruitment (361). Peritoneal IL-33 administration expands adipocyte precursors and promotes beige lineage commitment in an ILC2-dependent manner, as effects are abolished in the absence of ILC2s and when adipocyte precursors are not receptive to IL-4/IL-13 signaling (Il4r−/−Pdgfrα−) (359). An alternative mechanism of ILC2-dependent beiging of mouse adipose tissue was proposed by Brestoff et al. who found IL-33-stimulated ILC2s produce methionine-encephalin (MetEnk), an endogenous opioid-like peptide which induces WAT beiging (5). Overall, these studies demonstrate that ILC2-dependent eosinophil-derived IL-4 and ILC2-derived IL-13 and/or MetEnk directly promote murine adipocyte precursor proliferation and beige lineage commitment (5, 359).

Group 1 ILCs are largely resident in murine adipose tissue (362). Although their homeostatic role is poorly understood, ILC1s regulate adipose macrophage homeostasis (363). Alternatively activated macrophages scavenge potentially cytotoxic molecules released during adipose tissue remodeling and upregulate stress ligands (i.e. Rae-1) at steady state, and their selective depletion by adipose type 1 ILCs prevents stress-induced inflammation in macrophages during homeostatic tissue remodeling (363).

ILCs in Obesity

Dysregulation of the immune environment associated with obesity can lead to metabolic dysfunction and insulin resistance, driving type 2 diabetes (T2D) (364). ILC dysregulation has been implicated in obesity (Figure 11B). In obese humans and mice, ILC2s are reduced in WAT, possibly due to reduced IL-33 production by ASPCs in response to high fat diet (5, 360, 365). High PD-1 expression on ILC2s reduced IL-5 and IL-13 production, an effect partially rescued by macrophage depletion, suggesting PD-1/PD-L1 interactions between ILC2s and macrophages dampens ILC2 function in obese conditions in mice (365). Additionally, adipocyte-derived soluble ST2 is induced by obesity and interrupts IL-33 signaling, impairing ILC2 homeostasis (366). Infiltration of IFN-γ-producing cells also contributes to reduced ILC2 abundance and function, as IFN-γ directly represses ILC2s and counteracts IL-33 (357).

Obese mice fed a high fat diet had adipose tissue-specific IL-12-dependent accumulation of ILC1s with elevated IFN-γ production, resulting in insulin resistance and glucose intolerance (362, 367). Interestingly, CD56dim CD16+ ILCs accumulating during obesity have reduced cytotoxicity, a potential secondary mechanism contributing to macrophage accumulation and glucose intolerance (363). Wensveen et al. demonstrated NKp46 on adipose-resident mouse NK cells may regulate this effect (368). High fat diet-induced obesity triggered the expression of NCR1 ligands on adipocytes which promoted local NK cell proliferation and production of IFN-γ, inducing the differentiation of pro-inflammatory macrophages and promoting insulin resistance (368). Wang et al. further found that the ILC1 IFN-γ-dependent expansion of pro-inflammatory macrophages exacerbated adipose fibrosis by promoting TGF-β1 and pro-fibrotic programs in macrophages, resulting in higher collagen deposition (367).

In agreement with murine models, circulating and adipose ILC1s are increased in obese patients, especially those with T2D, and the abundance of ILC1s positively correlates with measures of glucose intolerance and insulin resistance (367). A unique subpopulation of CSF1R+IL6Rα+ NK cells is expanded in human and murine obesity (369). Selective depletion of this subset (Csfr−loxSTOPlox-DTR x NcrCre) resulted in decreased weight gain, better glucose tolerance, and insulin responsiveness in mice fed a high fat diet (369). Further, the expression of RORγt, lymphotoxin and IL-22 all elevated weight gain and adipose tissue size, paralleling findings that IL-22 from Th17 cells exacerbates inflammation in obesity (370, 371). The regulation of metabolism by intestinal ILC3s suggests a gut-adipose axis that remains to be explored. Overall, ILC2s mediate adipose homeostasis and are dysregulated in obesity, while ILC1s and potentially ILC3s have a role in exacerbating inflammation.

CONCLUDING REMARKS

Multiple parallels and differences between murine and human ILCs exist. Their evolutionarily conserved transcriptional programs and functional similarity emphasizes their
importance across multiple distinct phylogenetic branches. However, a better understanding of homologies and analogies in their surface receptor expression and function are needed to inform conserved mechanisms underlying responses to infections, inflammation and malignancies. This will be of particular interest to enhance our understanding NK cell biology, where receptors regulating NK cells responses differ between mouse and human, but different receptors often perform similar function.

The distinct living conditions of mice and humans require conserved and species-specific adaptations of organs and tissues to environmental triggers. ILCs as regulators of tissue homeostasis adapt to these species-specific environments. Shared and differing microbiota within humans and mice may explain conserved and distinct functions of ILCs across these organisms. Gnotobiotic technologies, humanized mice, knock-out mouse models or adoptive transfer experiments are suitable to investigate these differences but bring their own pitfalls. Beyond these challenges, a key obstacle for the study of ILCs in situ is the scarcity of ILC-specific models available to tease out cell-specific or even organ-specific functions. Adding to this, ILCs typically function in cellular networks to influence the outcome of a given immune response. To properly understand their function and tease out any redundancy, more systems-based approaches are needed, particularly in humans (295, 372, 373).

Other roadblocks in understanding the role of various ILCs in homeostasis and disease are studies designed only to link the presence or absence of ILCs with disease outcome. This is especially evident in reports of NK cell function. Reporting expansion or reduction of NK cells as having a protective or detrimental effect assumes a homogeneous function of NK cells. While classically, NK cell
function has been cytotoxic and inflammatory, NK cells have also been cast in an immunoregulatory role where they dampen an immune response (19). Additionally, identifying NK cells as CD3+CD56+ does not rule out other non-cytotoxic ILC1s and ILC3s that can share CD56 expression, and does not address the large degree of heterogeneity within NK cells (374). Untangling the identity and functional capacity of distinct CD3+CD56+ populations may help to clarify contradictory findings.

The plasticity of ILCs makes definitively assigning them as “good” or “bad” quite problematic. Sometimes ILCs with identical or similar surface phenotype may be functionally distinct (206). While this may be context dependent, ILC plasticity may be partially responsible for conflicting reports of their function in disease. Future studies should consider assessing the functional role of ILC subsets correlated with ILC transcriptional and epigenetic profiles to identify mechanisms underlying distinct ILC functions and whether some level of ‘trained’ immunity contributes to differing findings. Additionally, it remains unclear if the tissue-specific functions of ILCs are due in part to the existence of specific subsets of ILCs that home to their niche, or instead these different functions are a directly due to microenvironment signals leading to niche adaptation. It is also entirely possible that both cases are true and contribute to establishing tissue-specific ILC functions. Moving forward, the characterization of tissue-specific networks and niches for ILCs will transform our understanding of ILC functions and underlying mechanisms controlling their tissue adaptations.

AUTHOR CONTRIBUTIONS

All authors contributed to conceptualization, topic curation, writing and editing of the manuscript. Figures were designed by LN, with input from JM, AM, and SC. All authors contributed to the article and approved the submitted version.

FUNDING

JMM was supported by Queen Elizabeth II, Dick and Peggy Sharpe, and Peterborough KM Hunter Scholarships. LN was supported by an Ontario Graduate Scholarship and a NSERC-PGS award. AM's research program is supported by Canadian Institutes for Health Research (CIHR, 388337) and Natural Sciences and Engineering Research Council of Canada (NSERC, RGPIN-2019-04521), and is a Tier 2 Canadian Research Chair in Mucosal Immunology. SQC's research program is supported by funding from CIHR (168960 and 169084) and a NSERC (RGPIN-2021-03672), and is a Medicine By Design Investigator (Canada First Research Excellence Fund).

ACKNOWLEDGMENTS

All figures were created with BioRender.com.
109. Kim HY, Lee HJ, Chang YJ, Pichavant M, Shore SA, Fitzgerald KA, et al. Androgen Signaling Negatively Controls Group 2 Innate Lymphoid Cells. J Immunol (2017) 209:341–51. doi: 10.1164/rccm.201610-1916OC.

110. Levy BD, Bonnans C, Silverman ES, Palmer LJ, Marigowda C, Israel E. Diminished Lipoxin Biosynthesis in Severe Asthma. J Allergy Clin Immunol (2018) 141:243–51. doi: 10.1016/j.jaci.2017.06.037.

111. Mehlhop PD, Van de Rijn M, Brewer JP, Kisselgof AB, Geha RS, Oettgen HC, et al. CD40L, But Not CD40, Is Required for Allergen-Induced Bronchial Hyperresponsiveness in Mice. J Allergy Clin Immunol (2001) 108:430–8. doi: 10.1067/mai.2001.117929.

112. Roos AB, Sanden C, Mori M, Bjerner L, Stampfli MR, Erjefält JS. IL-17A Is Elevated in End-Stage Chronic Obstructive Pulmonary Disease and Contributes to Cigarette Smoke-Induced Lymphoid Neogenesis. Am J Respir Crit Care Med (2019) 191:2322–41. doi: 10.1164/rccm.201810-1861OC.

113. Shikhaghe MM, Björklund ÅK, Mjöberg J, Erjefält JS, Cornelissen AS, Ros XR, et al. Neurophilin-1 Is Expressed on Lymphoid Tissue Residing LT-i-Like Group 3 Innate Lymphoid Cells and Associated With Ectopic Lymphoid Aggregates. Cell Rep (2017) 18:1761–73. doi: 10.1016/j.celrep.2017.01.063.

114. Rangel-Moreno J, Carragher DM, de la Luz Garcia-Hernandez M, Hwang JY, Kusser K, Hartson L, et al. The Development of Inducible Bronchus-Associated Lymphoid Tissue Depends on IL-17. Nat Immunol (2011) 12:639–46. doi: 10.1038/ni.2053.

115. Fitch DK, Stolberg VR, Ferguson J, Alkai H, Kady MR, Richmond BW, et al. Lung Dendritic Cells Drive Natural Killer Cytotoxicity in Chronic Obstructive Pulmonary Disease via IL-15ra. Am J Respir Crit Care Med (2018) 198:1140–50. doi: 10.1164/rccm.201712-2513OC.

116. Osterburg AR, Lach L, Panos RJ, Borchers MT. Unique Natural Killer Cell Subpopulations are Associated With Exacerbation Risk in Chronic Obstructive Pulmonary Disease. Sci Rep (2020) 10:1–11. doi: 10.1038/s41598-020-38826-7.

117. Kearley J, Silver JS, Sanden C, Liu Z, Berlin AA, White N, et al. Cigarette Smoke Silences Innate Lymphoid Cell Function and Facilitates an Exacerbated Type I Interleukin-33-Dependent Response to Infection. Immunity (2015) 42:566–79. doi: 10.1016/j.immuni.2015.02.011.

118. Shikhagaie MM, Björklund ÅK, Mjösberg J, Erjefält JS, Cornelissen AS, Ros XR, et al. Neurophilin-1 Is Expressed on Lymphoid Tissue Residing LT-i-Like Group 3 Innate Lymphoid Cells and Associated With Ectopic Lymphoid Aggregates. Cell Rep (2017) 18:1761–73. doi: 10.1016/j.celrep.2017.01.063.

119. Rangel-Moreno J, Carragher DM, de la Luz Garcia-Hernandez M, Hwang JY, Kusser K, Hartson L, et al. The Development of Inducible Bronchus-Associated Lymphoid Tissue Depends on IL-17. Nat Immunol (2011) 12:639–46. doi: 10.1038/ni.2053.

120. Finch DK, Stolberg VR, Ferguson J, Alkai H, Kady MR, Richmond BW, et al. Lung Dendritic Cells Drive Natural Killer Cytotoxicity in Chronic Obstructive Pulmonary Disease via IL-15ra. Am J Respir Crit Care Med (2018) 198:1140–50. doi: 10.1164/rccm.201712-2513OC.

121. Osterburg AR, Lach L, Panos RJ, Borchers MT. Unique Natural Killer Cell Subpopulations are Associated With Exacerbation Risk in Chronic Obstructive Pulmonary Disease. Sci Rep (2020) 10:1–11. doi: 10.1038/s41598-020-38826-7.

122. Keanley J, Silver JS, Sanden C, Liu Z, Berlin AA, White N, et al. Cigarette Smoke Silences Innate Lymphoid Cell Function and Facilitates an Exacerbated Type I Interleukin-33-Dependent Response to Infection. Immunity (2015) 42:566–79. doi: 10.1016/j.immuni.2015.02.011.

123. Teunissen MBM, Munneke JM, Bernink JH, Spuls PI, Res PCM, Te Velde A, et al. Composition of Innate Lymphoid Cell Subsets in the Human Skin: Enrichment of NCR+ ILC3 in Lesional Skin and Blood of Psoriasis Patients. J Invest Dermatol (2014) 134:2351–60. doi: 10.1016/j.jid.2014.146.

124. Villanova F, Flatter B, Tosi I, Grys K, Sreeneebus H, Perera GK, et al. Characterization of Innate Lymphoid Cells in Human Skin and Blood Demonstrates Increase of NKP44+ ILC3 in Psoriasis. J Invest Dermatol (2014) 134:984–91. doi: 10.1016/j.jid.2013.477.

125. Simony Y, Newell EW. Dissecting Human ILC Heterogeneity: More Than Just Three Subsets. Immunology (2018) 153:297–303. doi: 10.1111/imn.12862.

126. Brüggen MC, Bauer WM, Reinnering B, Cimic E, Cattareuco C, Steiner GE, et al. In Situ Mapping of In innate Lymphoid Cells in Human Skin: Evidence for Remarkable Differences Between Normal and Inflamed Skin. J Invest Dermatol (2016) 136:2396–405. doi: 10.1016/j.jid.2016.07.017.

127. Simoni Y, Fehlings M, Kleverpris HN, McGovern N, Koo SL, Loh CY, et al. Human Innate Lymphoid Cell Subsets Possess Tissue-Type Based Heterogeneity in Phenotype and Frequency. Immunity (2017) 46:148–61. doi: 10.1016/j.immuni.2016.11.005.

128. Kobayashi T, Voisin B, Kim DY, Kennedy EA, Jo JH, Shih HY, et al. Homeostatic Control of Sebaceous Glands by Innate Lymphoid Cells Regulates Commensal Bacteria Equilibrium. Cell (2017) 169:982–97.e16. doi: 10.1016/j.cell.2018.12.031.

129. Adachi T, Kobayashi T, Sugihara E, Yamada T, Ikuta K, Pittaluga S, et al. Hair Follicle-Derived IL-7 and IL-15 Mediate Skin-Resident Memory T Cell Homeostasis and Lymphoma. Nat Med (2015) 21:1272–9. doi: 10.1038/nm.3962.

130. Soumelis V, Reche PA, Kanzler H, Yuan W, Edward G, Homey B, et al. Human Epithelial Cells Trigger Dendritic Cell-Mediated Allergic Inflammation by Producing TSLP. Nat Immunol (2002) 3:673–80. doi: 10.1038/ni805.

131. Chen YL, Gutowska-Owsiak D, Hardman CS, Westmoreland M, MacKenzie T, Ciftuentes I, et al. Proof-Of-Concept Clinical Trial of Etokimab Shows a Key Role for IL-33 in Atopic Dermatitis Pathogenesis. Sci Transl Med (2019) 11:eaax2945. doi: 10.1126/scitranslmed.aax2945.

132. Salimi M, Barlow JL, Saunders SP, Xue L, Gutowska-Owsiak D, Wang X, et al. A Role for IL-25 and IL-33-Driven Type-2 Innate Lymphoid Cells in Childhood Asthma. J Exp Med (2017) 214:351–62. doi: 10.1084/jem.20161007.

133. Wolk K, Witte E, Wallace E, Döcke WD, Kunz S, Asadullah K, et al. IL-22 Regulates the Expression of Genes Responsible for Antimicrobial Defense, Cellular Differentiation, and Mobility in Keratinocytes: A Potential Role in Psoriasis. Eur J Immunol (2006) 36:1309–23. doi: 10.1002/eji.200535503.
134. Erk CN, Yucel T, Yucel MA, Belkaid Y. Skin Microbiota-Host Interactions. *Nature* (2018) 553:427–36. doi: 10.1038/nature25177

135. Rak GD, Osborne LC, Siracusa MC, Kim BS, Wang K, Bayat A, et al. IL-33-Dependent Group 3 Innate Lymphoid Cells Promote Cutaneous Wound Healing. *J Invest Dermatol* (2016) 136:887–96. doi: 10.1038/JID.2015.406

136. Li Z, Hodgkinson T, Gothard BJ, Boroumand S, Lamb R, Cummins I, et al. Epidermal Notch1 Recruits Rorγ+ Group 3 Innate Lymphoid Cells to Orchestrates Normal Skin Repair. *Nat Commun* (2016) 7:1394. doi: 10.1038/ncomms11394

137. McGee HM, Schmidt BA, Booth CJ, Yancopoulos GD, Valenza DL, Murphy AJ, et al. IL-22 Promotes Fibroblast-Mediated Wound Repair in the Skin. *J Invest Dermatol* (2013) 133:1321–9. doi: 10.1038/JID.2012.463

138. Eyerich S, Eyerich K, Pennino D, Carbone T, Nasorri F, Pallotta S, et al. Th22 Cells Represent a Distinct Human T Cell Subset Involved in Epidermal Immunity and Remodeling. *J Clin Invest* (2009) 119:3573–85. doi: 10.1172/JCI40202

139. Kobayashi T, Ricardo-Gonzalez RR, Moro K. Skin-Resident Innate Lymphoid Cells – Cutaneous Innate Guardians and Regulators. *Trends Immunol* (2020) 41:100–12. doi: 10.1016/j.tit.2019.12.004

140. Di Cesare A, Di Meglio P, Nestle FO. The IL-23/Th17 Axis in the Induction of Interleukin-17 Pathway Genes in Nonlesional Skin of Moderate-to-Severe Psoriasis Vulgaris. *Br J Dermatol* (2016) 174:136–45. doi: 10.1111/bjd.14034

141. Muromoto R, Hiroo T, Tawa K, Hirashima K, Kon S, Kitai Y, et al. IL-17A Plays a Central Role in the Expression of Psoriasis Signature Genes Through the Induction of Ikbα in Keratinocytes. *Int Immunol* (2016) 28:443–52. doi: 10.1093/intimm/dxm011

142. Dyring-Andersen B, Geisler C, Agerbeck C, Lauritsen JPH, Gudjomsdottir SD, Skov L, et al. Increased Number and Frequency of Group 3 Innate Lymphoid Cells in Nonlesional Psoriatic Skin. *Br J Dermatol* (2014) 170:609–16. doi: 10.1111/bjd.12658

143. Tamoutounour S, Han SJ, Deckers J, Constantinides MG, Hurabille C, Harrison OJ, et al. Keratinocyte-Intrinsic MHCII Expression Controls Microbiota-Induced Th17 Cell Responses. *Proc Natl Acad Sci USA* (2019) 116:23643–52. doi: 10.1073/pnas.1912432116

144. Hardman CS, Chen YL, Castaneda SD, Skov L, et al. Peripheral Natural Killer Cells Exhibit Qualitative and Quantitative Differences in Nonlesional Skin Compared to Lesional Skin in Psoriasis. *Sci Immunol* (2015) 2:eaan5918. doi: 10.1126/sciimmunol.aan5918

145. Lucy C, Gaudy-Marquete C, Roupaire P, Audonnet S, Cognet C, Hennino A, et al. Peripheral Natural Killer Cells Exhibit Qualitative and Quantitative Differences in Psoriasis Skin Compared to Lesional Skin. *Sci Immunol* (2015) 2:eaan5918. doi: 10.1126/sciimmunol.aan5918

146. Emgård J, Kammoun H, Garcia-Cassani B, Chesné J, Parigi SM, Jacob JM, et al. Oxysterol Sensing Through the Receptor GPR183 Promotes the Lymphoid-Tissue-Inducing Function of Innate Lymphoid Cells and Colonic Inflammation. *Immunity* (2018) 48:120–32.e8. doi: 10.1016/j.immuni.2017.11.020

147. Monticelli LA, Osborne LC, Noti M, Tran SV, Zaisz DMW, Artis D. IL-33 Promotes an Innate Immune Pathway of Intestinal Tissue Protection Dependent on Amphiregulin-EGFR Interactions. *Proc Natl Acad Sci USA* (2015) 112:10762–7. doi: 10.1073/pnas.1509070112

148. Schneider C, deOlivear CE, von Molfke J, Liang HE, Ang QY, Turnbaugh PJ, et al. A Metabolite-Triggered Tuft Cell-ILC2 Circuit Drives Small Intestinal Remodeling. *Cell* (2018) 174:271–84.e14. doi: 10.1016/j.cell.2018.05.014

149. Hung LY, Tanaka Y, Herbine K, Pastore C, Singh B, Ferguson A, et al. Cellular Context of IL-33 Expression Dictates Impact on Anti-Helmintic Immunity. *Sci Immunol* (2020) 5:eabc6259. doi: 10.1126/sciimmunol.ab6259

150. Gronke K, Hernández PP, Zimmermann J, Klose CSN, Kofoed-Branz M, Guendel F, et al. Interleukin-22 Protects Intestinal Stem Cells Against Genotoxic Stress. *Nature* (2019) 566:249–53. doi: 10.1038/s41586-019-0899-x

151. Aparicio-Domingo P, Romera-Hernández M, Karrich JJ, Cornellissen F, Papazian N, Lindener-Korteve DJ, et al. Type 3 Innate Lymphoid Cells Maintain Intestinal Epithelial Stem Cells After Tissue Damage. *J Exp Med* (2015) 212:1783–91. doi: 10.1084/jem.201503018

152. Romera-Hernández M, Aparicio-Domingo P, Papazian N, Karrich JJ, Cornellissen F, Hoogenboom RM, et al. Yap1-Driven Intestinal Repair Is Controlled by Group 3 Innate Lymphoid Cells. *Cell Rep* (2020) 30:37–45.e3. doi: 10.1016/j.celrep.2019.11.115

153. Lindemanns CA, Calafaro M, Mertelsmann AM, O’Connor MH, Dudakov JA, Jenq RR, et al. Interleukin-22 Promotes Intestinal-Stem-Cell-Mediated Epithelial Regeneration. *Nature* (2015) 528:560–4. doi: 10.1038/nature16460

154. Thompson CL, Plummer SJ, Tucker TC, Casey G, Li L. Interleukin-22 Genetic Polymorphisms and Risk of Colon Cancer. *Cancer Causes Control* (2010) 21:1165–70. doi: 10.1007/s10555-010-9542-5

155. Yao J, Liu L, Yang M. Interleukin-23 Receptor Genetic Variants Contribute to Susceptibility of Multiple Cancers. *Gene* (2014) 533:21–5. doi: 10.1016/j.gene.2013.09.059

156. Pickard JM, Maurice CF, Kinnebrew MA, Abt MC, Schenten D, Golovkina TV, et al. Rapid Fucosylation of Intestinal Epithelium Sustains Host-Commensal Symbiosis in Sickness. *Nature* (2014) 514:638–41. doi: 10.1038/nature13823
209. Sandborn WJ, Feagan BG, Fedorak RN, Scher I, Fleisher MR, Katz S, et al. A Randomized Trial of Ustekinumab, a Human Interleukin-12/23 Monoclonal Antibody, in Patients With Moderate-To-Severe Crohn's Disease. Gastroenterology (2008) 135:1130–41. doi: 10.1053/j.gastro.2008.07.014

210. Creyts B, Jacobs I, Verstockt B, Cremer J, Ballet V, Vandecasteele R, et al. Biological Therapy in Inflammatory Bowel Disease Patients Partly Restores Intestinal Inflammatory Lymph Cell Subtype Equilibrium. Front Immunol (2020) 11:1847. doi: 10.3389/fimmu.2020.01847

211. Chen J, Haller CA, Jernigan FE, Koerner SK, Wong DJ, Wang Y, et al. Modulation of Lymphocytemediated Tissue Repair by Rational Design of Heterocyclic Aryl Hydrocarbon Receptor Agonists. Sci Adv (2020) 6:11-16. doi: 10.1126/sciadv.ay8230

212. Okada S, Markle JG, Deenick EK, Mele F, Averbuch D, Lagos M, et al. Perturbation of Mucosal Group 3 Innate Lymphoid and Natural Killer Cells Direct Goblet Cell Differentiation via T-Cell Mediated Ligation of the TLR-3-Dependent Immunity. Cell Mol Immunol (2016) 13:328-36. doi: 10.1038/cmi.2015.104

213. Horta TA, Egea L, Dann SM, Eckmann L, Kagnoff MF. GM-CSF-Facilitated Dendritic Cell Recruitment and Survival Govern the Intestinal Mucosal Response to a Mouse Enteric Bacterial Pathogen. Cell Host Microbe (2010) 7:515–63. doi: 10.1016/j.chom.2010.01.006

214. Zheng Y, Valdez PA, Danilenko DM, Hu Y, Sa SM, Gong Q, et al. Interleukin-22 Mediates Early Host Defense Against Attacking and Efacing Bacterial Pathogens. Nat Med (2008) 14:283-92. doi: 10.1038/nm.1772

215. Abt MC, Buffe CG, Saib A, Baccettini S, Carter RA, Leiner I, et al. TLR-7 Activation Enhances IL-22-Mediated Colonization Resistance Against Vancomycin-Resistant Enterococcus. Sci TranslMed (2016) 8:327ra25. doi: 10.1126/scitranslmed.aad6663

216. Zelante T, Iannitti RG, Cunha C, DeLuca A, Giovannini G, Pieraccini G, et al. Enteric Bacteria Induce Ifn-γ–Producing Hepatic Sinusoids T Cells. PloS One (2013) 8:e59723. doi: 10.1371/journal.pone.0065723

217. Pan Y, Chai Q, Ren B, Wang Y, Lv M, Qiu J, et al. Type 3 Innate Lymphoid Cells Direct Goblet Cell Differentiation via the LT–LiFR Pathway During Listeria Infection. J Immunol (2020) 205:453–63. doi: 10.4049/jimmunol.2000197

218. Songhet P, Barthel M, Stecher B, Müller AI, Kremer M, Hansson GC, et al. Stromal IFN-γ–Signaling Modulates Goblet Cell Function During Salmonella Typhimurium Infection. PloS One (2011) 6:36-39. doi: 10.1371/journal.pone.0022459

219. Castlemain MJ, Dillon SM, Purba C, Cogswell AC, McCarter M, Barker E, et al. Enteric Bacteria Induce Ifn-γ and Granzyme B From Human Colonic T Cells. Cell Mol Immunol (2013) 10:365-77. doi: 10.1038/cmi.2013.96

220. Hernández PP, Mahalákov T, Yang S, Schwierzek V, Nguyen N, Guendel F, et al. Interferon-γ and Interleukin 22 Act Synergistically for the Induction of Interferon-Stimulated Genes and Control of Rotavirus Infection. Nat Immunol (2015) 16:698-707. doi: 10.1038/ni.3180

221. Wang Y, Lifshitz L, Gellatly K, Vinton CL, Busman-Sahay K, McCauley S, et al. HIV-1-Induced Cytokines Deplete Homeostatic Innate Lymphoid Cells and Expand TCF7-Dependent Memory NK Cells. J Exp Med (2020) 207:6015-6027. doi: 10.1084/jem.202016151

222. Neill DR, Wang SH, Bellosi A, Flynn RJ, Daly M, Langford TK, et al. Nuocytes Represent a New Innate Effector Leukocyte That Mediates Type-2 Immunity. Nature (2010) 464:1366–70. doi: 10.1038/nature08990

223. Saenz SA, Siracusa MC, Perrigue JG, Spencer SP, Urban JF, Tocker JE, et al. IL25 Elicits a Multipotent Progenitor Cell Population That Promotes TH2 Cytokine Responses. Nature (2010) 464:1366–67. doi: 10.1038/nature08991

224. Anthony RM, Rutitsky LJ, Urban JF, Stadecker MJ, Gause WC. Protective Immune Mechanisms in Helminth Infection. Nat Rev Immunol (2007) 7:975–87. doi: 10.1038/nri2199

225. Oliphant CJ, Hwang YY, Walker JA, Salimi M, Wongsak JM, et al. MHClII-Mediated Dialog Between Group 2 Innate Lymphoid Cells and CD4+ T Cells Potentiates Type 2 Immunity and Promotes Parasitic Helminth Expulsion. Immunity (2014) 41:283–95. doi: 10.1016/j.immuni.2014.06.016

226. Chu C, Parkhurst CN, Zhang W, Zhou L, Yano H, Arifuzzaman M, et al. The ChA-T-Acetylcholine Pathway Promotes Group 2 Innate Lymphoid Cell Responses and Anti-Helminth Immunity. Sci Immunol (2021) 6:eabe3218. doi: 10.1126/sciimmunol.abae3218

227. Osbourn M, Soares DC, Vacca F, Cohen ES, Scott IC, Gregory WF, et al. HpAR1 Protein Secreted by a Helminth Parasite Suppresses Interleukin-33. Immunity (2017) 47:739–51.e5. doi: 10.1016/j.immuni.2017.09.015

228. Campbell L, Hepworth MR, Whittingham-Dowd J, Thompson S, Bancroft AJ, Hayes KS, et al. IL2c Mediate Systemic Innate Protection by Priming Mucus Production at Distal Mucosal Sites. J Exp Med (2019) 216:2714–23. doi: 10.1084/jem.20181806

229. Löser S, Smith KA, Maiels RM. Innate Lymphoid Cells in Hemolytic Infections—Obligatory or Accessory? Front Immunol (2019) 10:6620. doi: 10.3389/fimmu.2019.00620

230. Nausch N, Appleby LJ, Sparks AM, Midzi N, Mdlulu T, Mutapi F. Group 2 Innate Lymphoid Cell Proportions Are Diminished in Young Helminth Infected Children and Restored by Curative Anti-Helminthic Treatment. PloS Neg Trop Dis (2015) 9:1–16. doi: 10.1371/journal.pntd.0003627

231. Boyd A, Ribeiro JMC, Nutman TB. Human CD117 (Ckit)+ Innate Lymphoid Cells Are Tissue Resident in the Liver. Hepatology (2008) 47:729–36. doi: 10.1002/heap.22034

232. Protzer U, Maini MK, Knolle PA. Living in the Liver: Hepatic Infections. Nat Rev Immunol (2012) 12:201–13. doi: 10.1038/nri3169

233. Debnath L, Hailer B, Jakob B, Süsstrunk A, Pätzold J, Valla H, et al. Cutting Edge: Identiﬁcation and Characterization of Human Interleukin-33–Producing Innate Lymphoid Cells in Homeostasis and are Retained Within Hepatic Sinusoids via the Engagement of CCR5 and CXCR6 Pathways. J Autoimmun (2016) 66:40–50. doi: 10.1016/j.jaut.2015.08.011

234. Stegmann KA, Robertson F, Hansi N, Gill U, Pallant C, Christophides T, et al. CXCR6 Marks a Novel Subset of T-Bet–Low Eomes+ Natural Killer Cells Residing in Human Liver. Sci Rep (2016) 6:26157. doi: 10.1038/srep26157

235. Aw Yeang HX, Piersma SJ, Lin Y, Yang L, Malkova ON, Miner C, et al. Cutting Edge: Human CD49e–NK Cells Are Tissue Resident in the Liver. J Immunol (2017) 198:1417–22. doi: 10.4049/jimmunol.1601818

236. Marquardt N, Beizat V, Nyström S, Hengst J, Iverson MA, Kekäläinen E, et al. Cutting Edge: Identification and Characterization of Human Intrahepatic CD49a+NK Cells. J Immunol (2015) 194:2467–71. doi: 10.4049/jimmunol.1402576
Macrophage Infiltration in Lupus-Prone Mice. *Front Immunol* (2021) 12:58414. doi: 10.3389/fimmu.2021.584414

301. Miller D, Monsuur K, Gallo E, Flores Y, Romero R, Gomez-Lopez N. Innate Lymphoid Cells in the Maternal and Fetal Compartments. *Front Immunol* (2018) 9:2396. doi: 10.3389/fimmu.2018.02396

302. Gellersen B, Brosens IA, Brosens JJ. Decidualization of the Human Endometrium: Mechanisms, Functions, and Clinical Perspectives. *Semin Reprod Med* (2007) 25:445–53. doi: 10.1055/s-2007-991042

303. Colucci F. The Immunological Code of Pregnancy. *Science* (80-) (2019) 365:862–3. doi: 10.1126/science.aaw1300

304. Kopcow HD, Allan DSJ, Chen X, Rybalov B, Andzelm MM, Ge B, et al. Human Decidual NK Cells Form Immature Activating Synapses and Are Not Cytotoxic. *Proc Natl Acad Sci USA* (2005) 102:15563–8. doi: 10.1073/pnas.0507835102

305. Gaynor LM, Colucci F. Uterine Natural Killer Cells: Functional Distinctions and Influence on Pregnancy in Humans and Mice. *Front Immunol* (2017) 8:467. doi: 10.3389/fimmu.2017.00467

306. Kennedy PR, Chazara O, Gardner L, Ivanovska MA, Farrell LE, Xiong S, et al. Activating KIR2DS4 Is Expressed by Uterine NK Cells and Contributes to Successful Pregnancy. *J Immunol* (2016) 197:4292–300. doi: 10.4049/jimmunol.1601279

307. Kane N, Kelly R, Saunders PTK, Critchley HOD. Proliferation of Uterine Natural Killer Cells is Induced by Human Chorionic Gonadotropin and Mediated via the Mannose Receptor. *Endocrinology* (2009) 150:2882–8. doi: 10.1210/en.2008-1309

308. Vento-Tormo R, Efremova M, Botting RA, Turco MY, Vento-Tormo M, Meyer KB, et al. Single-Cell Reconstruction of the Early Maternal–Fetal Interface in Humans. *Nature* (2018) 563:347–53. doi: 10.1038/s41586-018-0698-6

309. Huhn O, Ivanovska MA, Gardner L, Holland head M, Stinchcombe JC, Chen P, et al. Distinctive Phenotypes and Functions of Innate Lymphoid Cells in Human Decidua During Early Pregnancy. *Nat Commun* (2020) 11:381. doi: 10.1038/s41467-019-14123-z

310. Strunez B, Bister J, Jonsson H, Filipovic I, Crona-Guterstam Y, Kvedaraite E, et al. Continuous Human Uterine NK Cell Differentiation in Response to Endometrial Regeneration and Pregnancy. *Sci Immunol* (2021) 6:eaab7800.

311. Ivanovska MA, Stiglmy N, Marquardt N, Westgren M, Gidlöf S, Börjström NK. Composition and Dynamics of the Uterine NK Cell KIR Repertoire in Menstrual Blood. *Macaul Immuno* (2017) 10(2):32–31. doi: 10.1038/ni.2016.50

312. Netea MG, Joosten LAB, Latz E, Mills KHG, Stunnenberg HG, Neill LAJO, et al. Trained Immunity: A Program of Innate Immune Memory in Health and Disease. *Science* (80-) (2017) 352:aaaf1098. doi: 10.1126/science.aaf1098

313. Gamield M, Goldman-Wohl D, Isaacson B, Gur C, Stein N, Yamin R, et al. Trained Memory of Human Uterine NK Cells Enhances Their Function in Subsequent Pregnancies. *Immunity* (2018) 48:951–62.e5. doi: 10.1016/j.immuni.2018.03.030

314. Kuon RJ, Weber M, Heger J, Santillán I, Vomstein K, Bär C, et al. Uterine Natural Killer Cells in Patients With Idiopathic Recurrent Miscarriage. *Am J Reprod Immunol* (2017) 78:1–4. doi: 10.1111/aji.12721

315. Chen X, Liu Y, Cheung WC, Zhao Y, Huang J, Chung JPW, et al. Increased Expression of Antiangiogenic Cytokines in CD56+ Uterine Natural Killer Cells From Women With Recurrent Miscarriage. *Cytochrome* (2018) 110:272–6. doi: 10.1016/j.cyto.2018.01.013

316. Lucas ES, Vrijenak P, Mutin J, Diniz-da-Costa MM, Brighton PJ, Kong CS, et al. Successful Pregnancy Loss Is Associated With a Pro-Senescent Decidual Response During the Peri-Implantation Window. *Commun Biol* (2020) 3:1–14. doi: 10.1038/s42003-020-0763-1

317. Brighton PJ, Maruyama Y, Fishwick K, Vrijenak P, Tewary S, Fujihara R, et al. Clearance of Senescent Decidual Cells by Uterine Natural Killer Cells in Cycling Human Endometrium. *Elife* (2017) 6:1–23. doi: 10.7554/eLife.31274.001

318. Crespo AC, Malik S, Dotiwala F, Ansara JA, Sen Santara S, Ingersoll K, et al. Decidual NK Cells Transfer Granulysin to Selectively Kill Bacteria in Tropoblasts. *Cell* (2020) 182:1123–1139.e18. doi: 10.1016/j.cell.2020.07.019

319. Vacca P, Pesce S, Greppi M, Fulcheri E, Munari E, Olive D, et al. PD-1 Is Expressed by and Regulates Human Group 3 Innate Lymphoid Cells in
Human Decidua. Mucosal Immunol (2019) 12:624–31. doi: 10.1038/s41385-019-0141-9

320. Crozatto D, Micheletti A, Montaldo E, Orecchia P, Loiacono F, Canegallo F, et al. Group 3 Innate Lymphoid Cells Regulate Neutrophil Migration and Function in Human Decidua. Mucosal Immunol (2016) 9:1372–83. doi: 10.1038/mi.2016.10

321. Thiruchelvam U, Wingfield M, O’Farrelly C. Increased uNK Progenitor Cells in Women With Endometriosis and Infertility Are Associated With Low Levels of Endometrial Stem Cell Factor. Am J Reprod Immunol (2016) 75:493–502. doi: 10.1111/aji.12486

322. Kanzaki H, Imai K, Hayatama H, Inoue T, Kojima K, Fujimoto M, et al. The Role of Cytokines in Human Endometrium: The Inhibitory Effect of IL-1 and TNF-α on In Vitro Decidualization and mRNA Expression of M-CSF, SCF and LIF in the Human Endometrium. Endocr J (1994) 41:S105–15. doi: 10.1507/endocrj.41.Supplement_S105

323. Hochdorfé T, Winkler C, Pardali K, Mjöberg J. Expression of C-Kit Discriminates Between Two Functionally Distinct Subsets of Human Type 2 Innate Lymphoid Cells. Eur J Immunol (2019) 49:884–93. doi: 10.1002/eji.201848006

324. Cupedo T, Crellin NK, Papazian N, Rombouts EL, Weijer K, Grogan JL, et al. Human Fetal Lymphoid Tissue-Inducer Cells Are Interleukin 17-Producing Precursors to RORC+CD127+ Natural Killer-Like Cells. Nat Immunol (2009) 10:66–74. doi: 10.1038/ni.1668

325. Miller JE, Lingegowda H, Symons LK, Bougie O, Young SL, Lessey BA, et al. Interleukin-33 Activates Group 2 Innate Lymphoid Cell Expansion and Modulates Endometriosis. JCI Insight (2021) 6:e149699. doi: 10.1172/jci.insight.149699

326. Sugahara T, Tanaka Y, Hamaguchi M, Fuji M, Shimura K, Ogawa K, et al. Reduced Innate Lymphoid Cells in the Endometrium of Women With Endometriosis. Am J Reprod Immunol (2022) 87(1):e13502. doi: 10.1111/aji.13502

327. Azziz R, Carmina E, Chen Z, Dunia A, Laven JSE, Legro RS, et al. Polycystic Ovary Syndrome. Nat Rev Dis Prim (2016) 2:16057. doi: 10.1038/nrdp.2016.57

328. Qi X, Yun C, Sun L, Xia J, Wu Q, Wang Y, et al. Gut Microbiota – Bile Acid Interleukin-22 Axis Orchestrates Polycystic Ovary Syndrome. Cell Rep (2020) 30:2989–3003.e6. doi: 10.1016/j.celrep.2020.02.040

329. Matteo M, Serviddio G, Massenzio F, Serviddio G, Castellana L, Picca G, et al. Reduced Percentage of Natural Killer Cells Associated With Impaired Cytokine Network in the Secretory Endometrium of Infertile Women With Polycystic Ovary Syndrome. Fertil Steril (2010) 94:2222–2227.e3. doi: 10.1016/j.fertnstert.2010.01.049

330. Deng Y, Wu S, Yang T, Meng M, Chen X, Chen S, et al. Unique Phenotypes of Heart Resident Type 2 Innate Lymphoid Cells. Front Immunol (2020) 11:3802. doi: 10.3389/fimmu.2020.03802

331. Bracamonte-Baran W, Chen G, Hou X, Talor MV, Choi HS, Davousto G, et al. Non-Cytotoxic Cardiac Innate Lymphoid Cells Are a Resident and Quiescent Type 2-Committed Population. Front Immunol (2019) 10:6364. doi: 10.3389/fimmu.2019.00634

332. Ghaedi M, Shen ZY, Orangi M, Martinez-Gonzalez I, Wei L, Lu X, et al. Single-Cell Analysis of Rorγt+ Tracer Mouse Lung Reveals ILC2 Subsets and Effector ILC2 Subsets. J Exp Med (2020) 217:8em2020.182293. doi: 10.1002/jem.2182293

333. Selaliturai A, Deswaere V, Kandalakis P, Tipping P, Toh BH, Bobik A, et al. Natural Killer (NK) Cells Augment Atherosclerosis by Cytotoxic-Dependent Mechanisms. Cardiovasc Res (2014) 102:128–37. doi: 10.1093/cvr/cvu016

334. Nour-Eldine W, Joffre J, Zibara K, Esposito B, Giraud A, Zeboudj L, et al. Genetic Depletion or Hyperresponsiveness of Natural Killer Cells Do Not Affect Atherosclerosis Development. Circ Res (2018) 122:47–57. doi: 10.1161/CIRCRESAHA.117.31743

335. Li J, Wu J, Zhang M, Zheng Y. Dynamic Changes of Innate Lymphoid Cells in Acute ST-Segment Elevation Myocardial Infarction and its Association With Clinical Outcomes. Sci Rep (2020) 10:5099. doi: 10.1038/s41598-020-61903-5

336. Backteman K, Ernerudh J, Jonasson L. Natural Killer (NK) Cell Deficit in Coronary Artery Disease: No Aberrations in Phenotype But Sustained Reduction of NK Cells Is Associated With Low-Grade Inflammation. Clin Exp Immunol (2014) 175:104–12. doi: 10.1111/cei.12210
Tissue-Adapted Functions of ILCs

Murphy et al.

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2022 Murphy, Ngai, Mortha and Crome. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
| Abbreviation | Description |
|--------------|-------------|
| AD | Atopic dermatitis |
| Ahr | Aryl hydrocarbon receptor |
| APC | Antigen presenting cell |
| AREG | Amphiregulin |
| ASPCs | Adipose stem and progenitor cells |
| CAD | Coronary artery disease |
| CD | Crohn’s disease |
| ChAT | Choline acetyltransferase |
| COPD | Chronic obstructive pulmonary disease |
| cNK cells | Conventional NK cells |
| CNS | Central nervous system |
| CP | Cryptopatches |
| CVB3 | Coxsackievirus B3 |
| dNK cells | Decidual Natural Killer cells |
| DC | Dendritic cell |
| dNK cells | Decidual Natural Killer cells |
| EAE | Experimental autoimmune encephalitis |
| EOMES | Eomesoderm |
| ESRD | End stage renal disease |
| FasL | Fas ligand |
| FasR2 | Free Fatty Acid Receptor 2 |
| FHL2 | Four And A Half LIM Domains 2 |
| GITR | Glucocorticoid-induced TNFR-related protein |
| GPR34 | G Protein-Coupled Receptor 34 |
| HBV | Hepatitis B virus |
| hCG | Human chorionic gonadotropin |
| HCV | Hepatitis C virus |
| HDM | House dust mite |
| hILC | helper ILC |
| IBD | Inflammatory bowel disease |
| ID | Inhibitor of DNA binding |
| IFN-γ | Interferon gamma |
| IL | Interleukin |
| ILC | Innate lymphoid cell |
| ILC1 | Group 1 innate lymphoid cell |
| ILC2 | Group 2 innate lymphoid cell |
| ILC210 | IL-10 producing ILC2 |
| ILC3 | Group 3 innate lymphoid cell |
| ILCre | Regulatory ILC |
| ILF | Isolated lymphoid follicle |
| IR | Ischemia reperfusion injury |
| KIR | Killer immunoglobulin receptor |
| KLRG1 | Killer cell lectin like receptor G1 |
| LN | Lupus nephritis |
| LP | Lamina propria |
| LTI | Lymphoid tissue inducer |
| LXA4 | Lipoxin A4 |
| MHC-I | Major histocompatibility complex class I |
| MHC-II | Major histocompatibility complex class II |
| miRNA | MicroRNA |
| MS | Multiple Sclerosis |
| NASH | Non-alcoholic steatohepatitis |
| NCR | Natural cytotoxicity receptor |
| PCOS | Polycystic ovary syndrome |
| RA | Retinoic acid |
| RORA | RAR-related orphan receptor A |
| RORC | RAR-related orphan receptor C |
| RSV | Respiratory syncytial virus |
| SCF | Stem cell factor |
| SCFA | Short chain fatty acid |
| scRNAseq | Single cell RNA sequencing |
| SLE | Systemic lupus erythematosus |
| sLT | Surface lymphotoksin |
| SP | Specialized pro-resolving mediator |
| T2D | Type 2 diabetes |
| TBET | T-box transcription factor |
| Th | T follicular helper |
| TGIT | T cell immunoreceptor with Ig and ITIM domains |
| TNF | Tumor necrosis factor |
| Treg | Regulatory T cell |
| TSIR | Thymic stromal lymphopoietin |
| UCP-1 | Uncoupling protein 1 |
| uNK cells | Uterine Natural Killer cells |
| VIP | Vasoactive intestinal peptide |
| WAT | White adipose tissue |
| AD | Atopic dermatitis |
| Ahr | Aryl hydrocarbon receptor |
| APC | Antigen presenting cell |
| AREG | Amphiregulin |
| ASPCs | Adipose stem and progenitor cells |
| CAD | Coronary artery disease |
| CD | Crohn’s disease |
| ChAT | Choline acetyltransferase |
| COPD | Chronic obstructive pulmonary disease |
| dNK cells | Decidual Natural Killer cells |
| CNS | Central nervous system |
| CP | Cryptopatches |
| CVB3 | Coxsackievirus B3 |
| dNK cells | Decidual Natural Killer cells |
| EAE | Experimental autoimmune encephalitis |
| EOMES | Eomesoderm |
| ESRD | End stage renal disease |
| FasL | Fas ligand |
| FasR2 | Free Fatty Acid Receptor 2 |
| FHL2 | Four And A Half LIM Domains 2 |
| GITR | Glucocorticoid-induced TNFR-related protein |
| GPR34 | G Protein-Coupled Receptor 34 |
| HBV | Hepatitis B virus |
| hCG | Human chorionic gonadotropin |
| HCV | Hepatitis C virus |
| HDM | House dust mite |
| hILC | helper ILC |
| IBD | Inflammatory bowel disease |
| ID | Inhibitor of DNA binding |
| IFN-γ | Interferon gamma |
| IL | Interleukin |
| ILC | Innate lymphoid cell |
| ILC1 | Group 1 innate lymphoid cell |
| ILC2 | Group 2 innate lymphoid cell |
| ILC210 | IL-10 producing ILC2 |
| ILC3 | Group 3 innate lymphoid cell |
| ILCre | Regulatory ILC |
| ILF | Isolated lymphoid follicle |
| IR | Ischemia reperfusion injury |
| KIR | Killer immunoglobulin receptor |
| KLRG1 | Killer cell lectin like receptor G1 |
| LN | Lupus nephritis |
| LP | Lamina propria |
| LTI | Lymphoid tissue inducer |
| LXA4 | Lipoxin A4 |
| MHC-I | Major histocompatibility complex class I |
| MHC-II | Major histocompatibility complex class II |
| miRNA | MicroRNA |
| MS | Multiple Sclerosis |
| NASH | Non-alcoholic steatohepatitis |
| NCR | Natural cytotoxicity receptor |
| PCOS | Polycystic ovary syndrome |
| RA | Retinoic acid |
| RORA | RAR-related orphan receptor A |
| RORC | RAR-related orphan receptor C |
| RSV | Respiratory syncytial virus |
| SCF | Stem cell factor |
| SCFA | Short chain fatty acid |
| scRNAseq | Single cell RNA sequencing |
| SLE | Systemic lupus erythematosus |
| sLT | Surface lymphotoksin |
| SP | Specialized pro-resolving mediator |

(Continued)
| Symbol | Term                          |
|--------|-------------------------------|
| RA     | Retinoic acid                 |
| RORA   | RAR-related orphan receptor A |
| RORC   | RAR-related orphan receptor C |
| RSV    | Respiratory syncytial virus   |
| SCF    | Stem cell factor              |
| SCFA   | Short chain fatty acid        |
| scRNAseq | Single cell RNA sequencing  |
| SLE    | Systemic lupus erythematosus  |
| sLT    | Surface lymphotoxin           |
| SPM    | Specialized pro-resolving mediator |
| T2D    | Type 2 diabetes               |
| TBET   | T-box transcription factor    |
| Th     | T follicular helper           |
| TIGIT  | T cell immunoreceptor with Ig and ITIM domains |
| TNF    | Tumor necrosis factor         |
| Treg   | Regulatory T cell             |
| TSLP   | Thymic stromal lymphopoietin  |
| UCP-1  | Uncoupling protein 1          |
| uNK cells | Uterine Natural Killer cells |
| VIP    | Vasoactive intestinal peptide |
| WAT    | White adipose tissue          |